NZ624317B2 - Overload and elute chromatography - Google Patents
Overload and elute chromatography Download PDFInfo
- Publication number
- NZ624317B2 NZ624317B2 NZ624317A NZ62431712A NZ624317B2 NZ 624317 B2 NZ624317 B2 NZ 624317B2 NZ 624317 A NZ624317 A NZ 624317A NZ 62431712 A NZ62431712 A NZ 62431712A NZ 624317 B2 NZ624317 B2 NZ 624317B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- chromatography
- polypeptide
- conductivity
- buffer
- Prior art date
Links
- 238000004587 chromatography analysis Methods 0.000 title claims abstract description 307
- 102000004965 antibodies Human genes 0.000 claims abstract description 464
- 108090001123 antibodies Proteins 0.000 claims abstract description 464
- 239000000463 material Substances 0.000 claims abstract description 250
- 238000011068 load Methods 0.000 claims abstract description 195
- 230000027455 binding Effects 0.000 claims abstract description 154
- 239000000203 mixture Substances 0.000 claims abstract description 138
- 239000012149 elution buffer Substances 0.000 claims abstract description 90
- 239000000356 contaminant Substances 0.000 claims abstract description 60
- 239000012160 loading buffer Substances 0.000 claims abstract description 49
- 238000011176 pooling Methods 0.000 claims abstract description 9
- 229920001184 polypeptide Polymers 0.000 claims description 351
- 102000004169 proteins and genes Human genes 0.000 claims description 135
- 108090000623 proteins and genes Proteins 0.000 claims description 135
- 239000000427 antigen Substances 0.000 claims description 79
- 108091007172 antigens Proteins 0.000 claims description 76
- 102000038129 antigens Human genes 0.000 claims description 76
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 55
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 50
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 50
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 29
- 238000005277 cation exchange chromatography Methods 0.000 claims description 28
- 230000035693 Fab Effects 0.000 claims description 26
- 238000005571 anion exchange chromatography Methods 0.000 claims description 26
- 238000001042 affinity chromatography Methods 0.000 claims description 24
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 238000005349 anion exchange Methods 0.000 claims description 15
- 239000006143 cell culture media Substances 0.000 claims description 15
- 108091006028 chimera Proteins 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 230000003612 virological Effects 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 9
- 241000699802 Cricetulus griseus Species 0.000 claims description 8
- 230000002209 hydrophobic Effects 0.000 claims description 8
- 238000005192 partition Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 6
- 210000001672 Ovary Anatomy 0.000 claims description 6
- 238000011026 diafiltration Methods 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 229960002518 gentamicin Drugs 0.000 claims description 6
- 238000011100 viral filtration Methods 0.000 claims description 6
- 239000002158 endotoxin Substances 0.000 claims description 5
- 108090000087 Carboxypeptidase B Proteins 0.000 claims description 4
- 102000003670 Carboxypeptidase B Human genes 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 description 129
- 239000000047 product Substances 0.000 description 123
- 239000011347 resin Substances 0.000 description 115
- 229920005989 resin Polymers 0.000 description 115
- 210000004027 cells Anatomy 0.000 description 103
- 238000010828 elution Methods 0.000 description 56
- 102000018358 Immunoglobulins Human genes 0.000 description 42
- 108060003951 Immunoglobulins Proteins 0.000 description 42
- 238000000034 method Methods 0.000 description 39
- 238000004519 manufacturing process Methods 0.000 description 33
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 31
- 229960000060 monoclonal antibodies Drugs 0.000 description 31
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 239000012535 impurity Substances 0.000 description 30
- 238000000746 purification Methods 0.000 description 28
- -1 for example Chemical class 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 239000012071 phase Substances 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 25
- 229920000023 polynucleotide Polymers 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 230000002829 reduced Effects 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 19
- 239000011534 wash buffer Substances 0.000 description 17
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 16
- 238000005341 cation exchange Methods 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 238000003530 single readout Methods 0.000 description 16
- 229910052720 vanadium Inorganic materials 0.000 description 16
- 108010071919 Bispecific Antibodies Proteins 0.000 description 15
- 230000004927 fusion Effects 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 210000004408 Hybridomas Anatomy 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000011020 pilot scale process Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 12
- 230000003899 glycosylation Effects 0.000 description 12
- 238000006206 glycosylation reaction Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000006011 modification reaction Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 102000004851 Immunoglobulin G Human genes 0.000 description 11
- 108090001095 Immunoglobulin G Proteins 0.000 description 11
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 239000006167 equilibration buffer Substances 0.000 description 10
- 230000037250 Clearance Effects 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 230000035512 clearance Effects 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 229940088598 Enzyme Drugs 0.000 description 8
- 108010087819 Fc receptors Proteins 0.000 description 8
- 102000009109 Fc receptors Human genes 0.000 description 8
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 239000012501 chromatography media Substances 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrugs Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229920001405 Coding region Polymers 0.000 description 7
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 7
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
- 230000003042 antagnostic Effects 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 230000001809 detectable Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 6
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 6
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 6
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 6
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 6
- 101710044656 FCGR3A Proteins 0.000 description 6
- 102100015541 FCGR3A Human genes 0.000 description 6
- 101710044657 FCGR3B Proteins 0.000 description 6
- 230000036328 Free drug Effects 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 230000000295 complement Effects 0.000 description 6
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002255 enzymatic Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth media Substances 0.000 description 6
- 229940020899 hematological Enzymes Drugs 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 6
- 108091008117 polyclonal antibodies Proteins 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101700009480 Fcgr3 Proteins 0.000 description 5
- 229940088597 Hormone Drugs 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 108010027440 Immunoconjugates Proteins 0.000 description 5
- 102000018748 Immunoconjugates Human genes 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 5
- 102000035443 Peptidases Human genes 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 231100000765 Toxin Toxicity 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001186 cumulative Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic Effects 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 210000001519 tissues Anatomy 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 108020003112 toxins Proteins 0.000 description 5
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 4
- 102100016790 HPRT1 Human genes 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 101700030421 fhuA Proteins 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002538 fungal Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 102100001249 ALB Human genes 0.000 description 3
- 102100008191 CD8A Human genes 0.000 description 3
- 101700054655 CD8A Proteins 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102100019442 ITGAL Human genes 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 3
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 3
- 229940047122 Interleukins Drugs 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 241000702623 Minute virus of mice Species 0.000 description 3
- 101700009327 NTF3 Proteins 0.000 description 3
- 102100015697 NTF3 Human genes 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 101710034683 Pput_4291 Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 3
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 101700019707 UBA1 Proteins 0.000 description 3
- 102100015249 VEGFA Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- 244000052616 bacterial pathogens Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108020004256 beta-Lactamases Proteins 0.000 description 3
- 102000006635 beta-Lactamases Human genes 0.000 description 3
- 230000001588 bifunctional Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- 101700081494 degP Proteins 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000011062 flow through chromatography Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 101700027776 mab-3 Proteins 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 238000003156 radioimmunoprecipitation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000003248 secreting Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholino)ethanesulfonic acid Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- GANZODCWZFAEGN-UHFFFAOYSA-N 5-Mercapto-2-Nitro-Benzoic Acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101700061329 ARTN Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102100005826 CD19 Human genes 0.000 description 2
- 101700087100 CD19 Proteins 0.000 description 2
- 102100013077 CD4 Human genes 0.000 description 2
- 101700022938 CD4 Proteins 0.000 description 2
- 210000003311 CFU-EM Anatomy 0.000 description 2
- 102100005310 CTLA4 Human genes 0.000 description 2
- 101700054183 CTLA4 Proteins 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
- 229940047120 Colony stimulating factors Drugs 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108009000280 Complement Activation Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 101700033006 EGF Proteins 0.000 description 2
- 102100010813 EGF Human genes 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 101700041204 ERBB3 Proteins 0.000 description 2
- 102000027776 ERBB3 Human genes 0.000 description 2
- 101700023619 ERBB4 Proteins 0.000 description 2
- 102100009851 ERBB4 Human genes 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 2
- 102100015545 FCGR2A Human genes 0.000 description 2
- 101710009074 FLT3 Proteins 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 241001190717 Hea Species 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 101710006573 ITGAL Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 231100000608 Immunotoxin Toxicity 0.000 description 2
- 108010004484 Immunotoxins Proteins 0.000 description 2
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 2
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 2
- 102400000022 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100000165 MS4A1 Human genes 0.000 description 2
- 101710010909 MS4A1 Proteins 0.000 description 2
- 239000012515 MabSelect SuRe Substances 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 210000001616 Monocytes Anatomy 0.000 description 2
- 102100016138 NTF4 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229920000272 Oligonucleotide Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000001322 Periplasm Anatomy 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 239000012518 Poros HS 50 resin Substances 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 229960000856 Protein C Drugs 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 108091008153 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 101700018328 ccdB Proteins 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000012561 harvest cell culture fluid Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 108060005018 mobB Proteins 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 101700002291 ompT Proteins 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 101700074470 pac Proteins 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 101700054060 phoA Proteins 0.000 description 2
- 101710016966 phoA2 Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920002496 poly(ether sulfone) Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N (2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-3-hydroxypropanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2S)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- YCHYFHOSGQABSW-RTBURBONSA-N (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- HIJXBFJPIKJPAF-UHFFFAOYSA-N 2-ethyl-1H-pyridine-4-thione Chemical compound CCC1=CC(S)=CC=N1 HIJXBFJPIKJPAF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-Phosphoglyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropan-1-amine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
- TUTIHHSZKFBMHM-UHFFFAOYSA-N 4-amino-5-[(3-amino-1-carboxy-3-oxopropyl)amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(CC(N)=O)C(O)=O TUTIHHSZKFBMHM-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 101710006356 ACTI Proteins 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100014858 AMH Human genes 0.000 description 1
- 101710026933 AMH Proteins 0.000 description 1
- 101710006703 AS Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- NPDLYUOYAGBHFB-UHFFFAOYSA-N Asparaginyl-Arginine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N NPDLYUOYAGBHFB-UHFFFAOYSA-N 0.000 description 1
- QJMCHPGWFZZRID-UHFFFAOYSA-N Asparaginyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC(N)=O QJMCHPGWFZZRID-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 1
- 229940090047 Auto-Injector Drugs 0.000 description 1
- 101710010420 BN863_22010 Proteins 0.000 description 1
- 101710010421 BN863_22020 Proteins 0.000 description 1
- 101710010411 BN863_22030 Proteins 0.000 description 1
- 101710010422 BN863_22070 Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N Bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- OCZUDQKWHCXYIG-UHFFFAOYSA-N CCC(O)=O.O=C1CCC(=O)N1N1C(C2C=CSS2)C=CC=C1 Chemical compound CCC(O)=O.O=C1CCC(=O)N1N1C(C2C=CSS2)C=CC=C1 OCZUDQKWHCXYIG-UHFFFAOYSA-N 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 101710041060 COX7A1 Proteins 0.000 description 1
- 101710017682 CPF_0221 Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 101700046715 CSTI Proteins 0.000 description 1
- 108050007957 Cadherins Proteins 0.000 description 1
- 102000000905 Cadherins Human genes 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical group 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 101700020566 DEFA4 Proteins 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101710034658 DNASE1 Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N Disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 102000007698 EC 1.1.1.1 Human genes 0.000 description 1
- 108010021809 EC 1.1.1.1 Proteins 0.000 description 1
- 108010073038 EC 3.5.1.11 Proteins 0.000 description 1
- 102000000311 EC 3.5.4.1 Human genes 0.000 description 1
- 108010080611 EC 3.5.4.1 Proteins 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 102000009071 ErbB Receptors Human genes 0.000 description 1
- 108010073043 ErbB Receptors Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102100006624 F9 Human genes 0.000 description 1
- 101700079540 FAS Proteins 0.000 description 1
- 102100015540 FCGR1A Human genes 0.000 description 1
- 101710003440 FCGR1A Proteins 0.000 description 1
- 101710044640 FCGR2A Proteins 0.000 description 1
- 102100015543 FCGR2B Human genes 0.000 description 1
- 101710044641 FCGR2B Proteins 0.000 description 1
- 101710044642 FCGR2C Proteins 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 102100014838 FCGRT Human genes 0.000 description 1
- 102100007155 FGF1 Human genes 0.000 description 1
- 101700064732 FGF1 Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 101710044881 GHRH Proteins 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 description 1
- 241001416183 Ginglymostomatidae Species 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- SSHIXEILTLPAQT-UHFFFAOYSA-N Glutaminyl-Aspartate Chemical compound NC(=O)CCC(N)C(=O)NC(CC(O)=O)C(O)=O SSHIXEILTLPAQT-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038586 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 101710006353 IP3R Proteins 0.000 description 1
- 101700035656 ISOTI Proteins 0.000 description 1
- 101710006572 ITGAM Proteins 0.000 description 1
- 102100019441 ITGAM Human genes 0.000 description 1
- 101710006689 ITGAX Proteins 0.000 description 1
- 102100019437 ITGAX Human genes 0.000 description 1
- 102100001475 ITGB2 Human genes 0.000 description 1
- 101710006663 ITGB2 Proteins 0.000 description 1
- 101700035039 ITI Proteins 0.000 description 1
- 101700052013 ITR2 Proteins 0.000 description 1
- 101700068039 ITRP Proteins 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000004090 Immunoglobulin Isotypes Human genes 0.000 description 1
- 108090000539 Immunoglobulin Isotypes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 101800001819 Insulin A chain Proteins 0.000 description 1
- 102400000453 Insulin A chain Human genes 0.000 description 1
- 101800000896 Insulin B chain Proteins 0.000 description 1
- 102400000454 Insulin B chain Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N L-tyrosyl-L-tyrosine Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 229940040129 Luteinizing Hormone Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 101710027015 MIMI_R382 Proteins 0.000 description 1
- 101700013924 MITF Proteins 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101700036939 MTI Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001441512 Maytenus serrata Species 0.000 description 1
- 229960003151 Mercaptamine Drugs 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 240000004175 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WSTNFGAKGUERTC-UHFFFAOYSA-N N-ethylhexan-1-amine Chemical compound CCCCCCNCC WSTNFGAKGUERTC-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102100009139 NGF Human genes 0.000 description 1
- 101700079360 NTF4 Proteins 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 229940032018 Neurotrophin 3 Drugs 0.000 description 1
- 108090000742 Neurotrophin-3 Proteins 0.000 description 1
- 102000004230 Neurotrophin-3 Human genes 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 101700070247 OSA15 Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229940043515 Other immunoglobulins in ATC Drugs 0.000 description 1
- 229940075461 Other therapeutic products in ATC Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 101700059656 PSAG Proteins 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 102100000775 REN Human genes 0.000 description 1
- 101710004305 RIP30A Proteins 0.000 description 1
- 101700000014 RIPS Proteins 0.000 description 1
- 101710002944 RLN Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 101800000074 Relaxin A chain Proteins 0.000 description 1
- 102400000834 Relaxin A chain Human genes 0.000 description 1
- 102400000610 Relaxin B chain Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M Sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide Dismutase Proteins 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 101700038204 TGFA Proteins 0.000 description 1
- 101700062451 TI Proteins 0.000 description 1
- 101700057439 TOXA Proteins 0.000 description 1
- 102100001172 TPPP Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 240000002223 Vigna mungo Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940099073 Xolair Drugs 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000004931 aggregating Effects 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002494 anti-cea Effects 0.000 description 1
- 230000001455 anti-clotting Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000003432 anti-folate Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000941 anti-staphylcoccal Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 101700067277 chxA Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000001447 compensatory Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001351 cycling Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 229960004222 factor IX Drugs 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 101700068417 fol1 Proteins 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 230000002414 glycolytic Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 101700068005 hbhA Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 101700066608 ilvG Proteins 0.000 description 1
- 150000002463 imido esters Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108010082095 insulin-like growth factor 1, des-(1-3)- Proteins 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 101700063896 mac-1 Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108010087335 neurotrophin 5 Proteins 0.000 description 1
- 108090000095 neurotrophin 6 Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000001293 nucleolytic Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 102000025475 oncoproteins Human genes 0.000 description 1
- 108091008124 oncoproteins Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002138 osteoinductive Effects 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000003623 progesteronic Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 101700034429 prsG Proteins 0.000 description 1
- 101700032180 psaA Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 229920000593 repetitive DNA sequence Polymers 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000012607 strong cation exchange resin Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical compound OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/14—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the introduction of the feed to the apparatus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Abstract
Disclosed is a method for purifying an antibody from a composition comprising the antibody and one or more contaminants, said method comprising a) loading the composition onto a chromatography material in an amount in excess of the dynamic binding capacity of the chromatography material for the antibody, b) eluting the antibody from the chromatography material under conditions wherein the one or more contaminants remain bound to the chromatography material, and c) pooling fractions comprising the antibody in the chromatography effluent from steps a) and b), wherein the loading density of the composition is between about 200 g/L to about 1000 g/L and wherein the method further comprises the use of a loading buffer and an elution buffer, wherein the elution buffer has a conductivity less than the conductivity of the loading buffer. ibody, b) eluting the antibody from the chromatography material under conditions wherein the one or more contaminants remain bound to the chromatography material, and c) pooling fractions comprising the antibody in the chromatography effluent from steps a) and b), wherein the loading density of the composition is between about 200 g/L to about 1000 g/L and wherein the method further comprises the use of a loading buffer and an elution buffer, wherein the elution buffer has a conductivity less than the conductivity of the loading buffer.
Description
OVERLOAD AND ELUTE CHROMATOGRAPHY
RELATED APPLICATIONS
This application claims the priority benefit of provisional patent application U.S. Serial
No. 61/554,898 filed November 2, 2011, which is hereby incorporated by reference in its
entirety.
FIELD OF THE INVENTION
The present invention generally provides methods for purifying a product from a
composition comprising the product and at least one contaminant. Also described are
formulations comprising the product purified by the methods.
BACKGROUND OF THE INVENTION
Anion exchange (AEX) chromatography is widely used in a flow-through mode as a
platform polishing step for monoclonal antibodies (MAbs). Certain MAbs that bind to AEX
resin under standard flow through conditions can pose plant fit challenges. For early stage
clinical development where the mass requirement is typically low, these non-platform MAbs
have been purified by using AEX or mixed mode resin in a bind and elute mode. However, due
to low dynamic binding capacity (DBC) of these resins, the late stage implementation would
require columns that are approximately 1000 L in size or multiple cycles on a smaller column
thus limiting the plant throughput.
MAb purification is typically performed using bind and elute chromatography (B/E) or
flow-through (F/T) chromatography. Recently weak partitioning chromatography (Kelley, BD
et al., 2008 Biotechnol Bioeng 101(3):553-566; US Patent Application Publication No. 2007/
0060741) and overload chromatography () have been introduced on AEX
resins and cation exchange (CEX) resins respectively to enhance MAb purification. The general
mechanism and limitations of each of these chromatography modes are highlighted below.
Bind and Elute Chromatography: Under B/E chromatography the product is usually
loaded to maximize DBC to the chromatography material and then wash and elution conditions
are identified such that maximum product purity is attained in the eluate. A limitation of B/E
chromatography is the restriction of the load density to the actual resin DBC
Flow Through Chromatography: Using F/T chromatography, load conditions are
identified where impurities strongly bind to the chromatography material while the product
flows through. F/T chromatography allows high load density for standard MAbs but may not be
implementable for non-platform MAbs or the solution conditions that enable F/T operation for
these non-platform MAbs may be such that they are not implementable in existing
manufacturing plants.
Weak Partitioning Chromatography: This mode of operation enhances the F/T mode
by identifying solution conditions where there is weak binding of MAb to the resin (2 to 20 g/L).
Under these conditions the impurities bind stronger than in the F/T mode and thus enhanced
purification is obtained. However, load conditions are targeted to a have a low product partition
coefficient (K ) in the range of 0.1-20.
Overload Chromatography: In this mode of chromatography the product of interest is
loaded beyond the dynamic binding capacity of the chromatography material for the product,
thus referred to as overload. The mode of operation has been demonstrated to provide MAb
purification with cation exchange (CEX) media and particularly with membranes. However, a
limitation of this approach is that there could be low yields with resin as there is no elution
phase.
The large-scale, cost-effective purification of a polypeptide to sufficient purity for use
as a human therapeutic remains a formidable challenge.
All references cited herein, including patent applications and publications, are
incorporated by reference in their entirety.
BRIEF SUMMARY
In one aspect, the invention provides a method for purifying an antibody from a
composition comprising the antibody and one or more contaminants, said method comprising
a) loading the composition onto a chromatography material in an amount in excess of the
dynamic binding capacity of the chromatography material for the antibody,
b) eluting the antibody from the chromatography material under conditions wherein the
one or more contaminants remain bound to the chromatography material, and
c) pooling fractions comprising the antibody in the chromatography effluent from steps
a) and b), wherein the loading density of the composition is between about 200 g/L to about
1000 g/L and wherein the method further comprises the use of a
loading buffer and an elution buffer, wherein the elution buffer has a conductivity less than the
conductivity of the loading buffer.
[0011a] Certain statements that appear below are broader than what appears in the statements of
the invention above. These statements are provided in the interests of providing the reader with
a better understanding of the invention and its practice. The reader is directed to the
accompanying claim set which defines the scope of the invention.
[0011b] Also described are methods for purifying a polypeptide from a composition comprising
the polypeptide and one or more contaminants, said method comprising a) loading the
composition onto a chromatography material in an amount in excess of the dynamic binding
capacity of the chromatography material for the polypeptide, b) eluting the polypeptide from the
chromatography material under conditions wherein the one or more contaminants remain bound
to the chromatography material, and c) pooling fractions comprising the polypeptide in the
chromatography effluent from steps a) and b).
In some embodiments, the polypeptide is an antibody or immunoadhesin. In some
embodiments, the antibody is a monoclonal antibody; for example, but not limited to a chimeric
antibody, humanized antibody, or human antibody.
In some embodiments, the antibody is an antigen binding fragment; for example but
not limited to a Fab fragment, a Fab’ fragment, a F(ab’)2 fragment, a scFv, a di-scFv, a bi-scFv,
a tandem (di, tri)-scFv, a Fv, a sdAb, a tri-functional antibody, a BiTE, a diabody and a triabody.
In some embodiments, the polypeptide is an enzyme, a hormone, a fusion protein, an
Fc-containing protein, an immunoconjugate, a cytokine or an interleukin.
In some embodiments, the polypeptide is purified from a composition comprising one
or more contaminants; for example, Chinese Hamster Ovary Protein (CHOP), a host cell protein
(HCP), leached protein A, carboxypeptidase B, nucleic acid, DNA, product variants, aggregated
protein, cell culture media component, gentamicin, polypeptide fragments, endotoxins, and viral
contaminant.
In some embodiments of the invention, the chromatography material is selected from a
mixed mode material, an anion exchange material, a hydrophobic interaction material, and an
affinity material.
In some embodiments, the composition is loaded onto the chromatography material at
about the dynamic binding capacities of the chromatography materials for the one or more
contaminants.
In some embodiments, the partition coefficient of the chromatography material for the
polypeptide is greater than 30 or greater than 100.
In some embodiments, the methods provide OEC wherein the elution buffer has
conductivity less than the conductivity of the loading buffer. In other embodiments, the elution
buffer has conductivity greater than the conductivity of the loading buffer. In some
embodiments, the methods provide OEC wherein the elution buffer has a pH less than the pH of
the loading buffer. In other embodiments, the elution buffer has a pH greater than the pH of the
loading buffer.
In some embodiments, the polypeptide of the methods is in an eluent from an affinity
chromatography, a cation exchange chromatography, an anion exchange chromatography, a
mixed mode chromatography and a hydrophobic interaction chromatography. In some
embodiments, the polypeptide is in an eluent from a Protein A chromatography.
In some embodiments, the polypeptide of the methods is further purified; for example,
by virus filtration, affinity chromatography, cation exchange chromatography, anion exchange
chromatography, mixes mode chromatography, and/or hydrophobic interaction chromatography.
In some embodiments, the polypeptide is further concentrated; for example by ultrafiltration,
diafiltration or a combination of ultrafiltration and diafiltration. In some embodiments, the
polypeptide of the methods is further combined with a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows high throughput screening (HTS) results on Capto Adhere resin under
batch binding conditions for MAb 3. Figure 1A shows contours of constant values of K for
MAb 3. Figure 1B shows actual binding capacity of MAb 3 in the supernatant at 80 g/L product
challenge to the resin. Figure 1C shows actual binding capacity of the impurity (host cell
protein) in the supernatant at 80 g/L product challenge to the resin. All the contour plots were
generated using a response surface model derived from the raw data.
Figure 2 shows a chromatogram for an optimized OEC mode of operation. MAb 3 was
used for this run with a load density of 180 g/L.
Figure 3 shows load optimization for an OEC mode using MAb 3.
Figure 4 shows a chromatogram with target load conditions for an OEC mode of
operation. Similar load and elution conditions results in tailing and thus a 45% increase in pool
volume. MAb 3 was used for this run with a load density of 180 g/L.
Figure 5 shows elution optimization for OEC mode using MAb 3.
Figure 6 shows impurity analysis in fractions and cumulative analysis of impurities.
Figure 7 shows MAb 3 CHOP breakthrough analysis of Capto Adhere resin under
OEC mode at a loading density of 1000 g/L.
Figure 8 shows yield analysis across pilot scale runs over a wide range of load
densities from 70 g/L to 180 g/L.
Figure 9 shows a comparison of weak partition chromatography mode of operation and
overload and elute chromatography mode operation. The product was MAb 3 and the
chromatography material was a Capto Adhere resin.
Figure 10 shows MAb 3 CHOP analysis on QMA resin under OEC mode of operation
at a load density of 150 g/L.
Figure 11 shows MAb 4 CHOP analysis on Capto Adhere resin under OEC mode of
operation at a load density of 150 g/L.
Figure 12 shows MAb 4 CHOP analysis on Capto MMC resin under OEC mode of
operation at a load density of 150 g/L.
Figure 13 shows MAb 3 CHOP breakthrough analysis on Capto Adhere resin under
OEC mode at a loading density of 200 g/L. MAb 3 protein A pool was loaded on Capto Adhere
resin to 200 g/L (which is beyond its 50 g/L product binding capacity). CHOP breakthrough
analysis showed that the CHOP did not breakthrough up to 200 g/L MAb processing.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
The term ‘comprising’ as used in this specification and claims means ‘consisting at
least in part of’. When interpreting statements in this specification and claims which includes
the ‘comprising’, other features besides the features prefaced by this term in each statement can
also be present. Related terms such as ‘comprise’ and ‘comprised’ are to be interpreted in
similar manner.
[0035a] The term “product” as described herein is the substance to be purified by OEC; for
example, a polypeptide.
The term “polypeptide” or “protein” are used interchangeably herein to refer to
polymers of amino acids of any length. The polymer may be linear or branched, it may
comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also
encompass an amino acid polymer that has been modified naturally or by intervention; for
example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or
any other manipulation or modification, such as conjugation with a labeling component. Also
included within the definition are, for example, polypeptides containing one or more analogs of
an amino acid (including, for example, unnatural amino acids, etc.), as well as other
modifications known in the art. The terms "polypeptide" and "protein" as used herein
specifically encompass antibodies.
“Purified” polypeptide (e.g., antibody or immunoadhesin) means that the polypeptide
has been increased in purity, such that it exists in a form that is more pure than it exists in its
natural environment and/or when initially synthesized and/or amplified under laboratory
conditions. Purity is a relative term and does not necessarily mean absolute purity.
The term “epitope tagged” when used herein refers to a chimeric polypeptide
comprising a polypeptide fused to a “tag polypeptide.” The tag polypeptide has enough residues
to provide an epitope against which an antibody can be made, yet is short enough such that it
does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide
preferably also is fairly unique so that the antibody does not substantially cross-react with other
epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually
between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid
residues).
“Active” or “activity” for the purposes herein refers to form(s) of a polypeptide which
retain a biological and/or an immunological activity of native or naturally-occurring polypeptide,
wherein “biological” activity refers to a biological function (either inhibitory or stimulatory)
caused by a native or naturally-occurring polypeptide other than the ability to induce the
production of an antibody against an antigenic epitope possessed by a native or naturally-
occurring polypeptide and an “immunological” activity refers to the ability to induce the
production of an antibody against an antigenic epitope possessed by a native or naturally-
occurring polypeptide.
The term “antagonist” is used in the broadest sense, and includes any molecule that
partially or fully blocks, inhibits, or neutralizes a biological activity of a native polypeptide. In a
similar manner, the term “agonist” is used in the broadest sense and includes any molecule that
mimics a biological activity of a native polypeptide. Suitable agonist or antagonist molecules
specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino
acid sequence variants of native polypeptides, etc. Methods for identifying agonists or
antagonists of a polypeptide may comprise contacting a polypeptide with a candidate agonist or
antagonist molecule and measuring a detectable change in one or more biological activities
normally associated with the polypeptide.
“Complement dependent cytotoxicity” or “CDC” refers to the ability of a molecule to
lyse a target in the presence of complement. The complement activation pathway is initiated by
the binding of the first component of the complement system (C1q) to a molecule (e.g.
polypeptide (e.g., an antibody)) complexed with a cognate antigen. To assess complement
activation, a CDC assay, e.g. as described in Gazzano-Santoro et al., J. Immunol. Methods
202:163 (1996), may be performed.
A polypeptide “which binds” an antigen of interest, e.g. a tumor-associated
polypeptide antigen target, is one that binds the antigen with sufficient affinity such that the
polypeptide is useful as a diagnostic and/or therapeutic agent in targeting a cell or tissue
expressing the antigen, and does not significantly cross-react with other polypeptides. In such
embodiments, the extent of binding of the polypeptide to a “non-target” polypeptide will be less
than about 10% of the binding of the polypeptide to its particular target polypeptide as
determined by fluorescence activated cell sorting (FACS) analysis or radioimmunoprecipitation
(RIA).
With regard to the binding of a polypeptide to a target molecule, the term “specific
binding” or “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a
particular polypeptide target means binding that is measurably different from a non-specific
interaction. Specific binding can be measured, for example, by determining binding of a
molecule compared to binding of a control molecule, which generally is a molecule of similar
structure that does not have binding activity. For example, specific binding can be determined
by competition with a control molecule that is similar to the target, for example, an excess of
non-labeled target. In this case, specific binding is indicated if the binding of the labeled target
to a probe is competitively inhibited by excess unlabeled target.
The term “antibody” herein is used in the broadest sense and specifically covers
monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific
antibodies) formed from at least two intact antibodies, and antibody fragments so long as they
exhibit the desired biological activity. The term “immunoglobulin” (Ig) is used interchangeable
with antibody herein.
Antibodies are naturally occurring immunoglobulin molecules which have varying
structures, all based upon the immunoglobulin fold. For example, IgG antibodies have two
“heavy” chains and two “light” chains that are disulphide-bonded to form a functional antibody.
Each heavy and light chain itself comprises a “constant” (C) and a “variable” (V) region. The V
regions determine the antigen binding specificity of the antibody, whilst the C regions provide
structural support and function in non-antigen-specific interactions with immune effectors. The
antigen binding specificity of an antibody or antigen-binding fragment of an antibody is the
ability of an antibody to specifically bind to a particular antigen.
The antigen binding specificity of an antibody is determined by the structural
characteristics of the V region. The variability is not evenly distributed across the 110-amino
acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches
called framework regions (FRs) of 15-30 amino acids separated by shorter regions of extreme
variability called “hypervariable regions” that are each 9-12 amino acids long. The variable
domains of native heavy and light chains each comprise four FRs, largely adopting a β-sheet
configuration, connected by three hypervariable regions, which form loops connecting, and in
some cases forming part of, the β-sheet structure. The hypervariable regions in each chain are
held together in close proximity by the FRs and, with the hypervariable regions from the other
chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al.,
Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in
binding an antibody to an antigen, but exhibit various effector functions, such as participation of
the antibody in antibody dependent cellular cytotoxicity (ADCC).
Each V region typically comprises three complementarity determining regions
(“CDRs”, each of which contains a “hypervariable loop”), and four framework regions. An
antibody binding site, the minimal structural unit required to bind with substantial affinity to a
particular desired antigen, will therefore typically include the three CDRs, and at least three,
preferably four, framework regions interspersed there between to hold and present the CDRs in
the appropriate conformation. Classical four chain antibodies have antigen binding sites which
are defined by V and V domains in cooperation. Certain antibodies, such as camel and shark
antibodies, lack light chains and rely on binding sites formed by heavy chains only. Single
domain engineered immunoglobulins can be prepared in which the binding sites are formed by
heavy chains or light chains alone, in absence of cooperation between V and V .
The term “variable” refers to the fact that certain portions of the variable domains
differ extensively in sequence among antibodies and are used in the binding and specificity of
each particular antibody for its particular antigen. However, the variability is not evenly
distributed throughout the variable domains of antibodies. It is concentrated in three segments
called hypervariable regions both in the light chain and the heavy chain variable domains. The
more highly conserved portions of variable domains are called the framework regions (FRs).
The variable domains of native heavy and light chains each comprise four FRs, largely adopting
a β-sheet configuration, connected by three hypervariable regions, which form loops connecting,
and in some cases forming part of, the β-sheet structure. The hypervariable regions in each chain
are held together in close proximity by the FRs and, with the hypervariable regions from the
other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et
al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in
binding an antibody to an antigen, but exhibit various effector functions, such as participation of
the antibody in antibody dependent cellular cytotoxicity (ADCC).
The term “hypervariable region” when used herein refers to the amino acid residues of
an antibody that are responsible for antigen binding. The hypervariable region may comprise
amino acid residues from a “complementarity determining region” or “CDR” (e.g., around about
residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the V , and around about 31-35B (H1), 50-65
(H2) and 95-102 (H3) in the V (Kabat et al., Sequences of Proteins of Immunological Interest,
5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those
residues from a “hypervariable loop” (e.g. residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the
V , and 26-32 (H1), 52A-55 (H2) and 96-101 (H3) in the V (Chothia and Lesk J. Mol. Biol.
196:901-917 (1987)).
“Framework” or “FR” residues are those variable domain residues other than the
hypervariable region residues as herein defined.
“Antibody fragments” comprise a portion of an intact antibody, preferably comprising
the antigen binding region thereof. Examples of antibody fragments include Fab, Fab', F(ab') ,
and Fv fragments; diabodies; tandem diabodies (taDb), linear antibodies(e.g., U.S. Patent No.
,641,870, Example 2; Zapata et al., Protein Eng. 8(10):1057-1062 (1995)); one-armed
antibodies, single variable domain antibodies, minibodies, single-chain antibody molecules;
multispecific antibodies formed from antibody fragments (e.g., including but not limited to, Db-
Fc, taDb-Fc, taDb-CH3, (scFV)4-Fc, di-scFv, bi-scFv, or tandem (di,tri)-scFv); and Bi-specific
T-cell engagers (BiTEs).
Papain digestion of antibodies produces two identical antigen-binding fragments,
called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment,
whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab') fragment
that has two antigen-binding sites and is still capable of cross-linking antigen.
“Fv” is the minimum antibody fragment that contains a complete antigen-recognition
and antigen-binding site. This region consists of a dimer of one heavy chain and one light chain
variable domain in tight, non-covalent association. It is in this configuration that the three
hypervariable regions of each variable domain interact to define an antigen-binding site on the
surface of the V -V dimer. Collectively, the six hypervariable regions confer antigen-binding
specificity to the antibody. However, even a single variable domain (or half of an Fv comprising
only three hypervariable regions specific for an antigen) has the ability to recognize and bind
antigen, although at a lower affinity than the entire binding site.
The Fab fragment also contains the constant domain of the light chain and the first
constant domain (CH1) of the heavy chain. Fab’ fragments differ from Fab fragments by the
addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one
or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in
which the cysteine residue(s) of the constant domains bear at least one free thiol group. F(ab')
antibody fragments originally were produced as pairs of Fab' fragments that have hinge
cysteines between them. Other chemical couplings of antibody fragments are also known.
The “light chains” of antibodies (immunoglobulins) from any vertebrate species can be
assigned to one of two clearly distinct types, called kappa ( κ) and lambda ( λ), based on the
amino acid sequences of their constant domains.
Depending on the amino acid sequence of the constant domain of their heavy chains,
antibodies can be assigned to different classes. There are five major classes of intact antibodies:
IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses
(isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant domains that
correspond to the different classes of antibodies are called α, δ, ε, γ, and μ, respectively. The
subunit structures and three-dimensional configurations of different classes of immunoglobulins
are well known.
“Single-chain Fv” or “scFv” antibody fragments comprise the V and V domains of
antibody, wherein these domains are present in a single polypeptide chain. In some
embodiments, the Fv polypeptide further comprises a polypeptide linker between the V and V
domains that enables the scFv to form the desired structure for antigen binding. For a review of
scFv see Plückthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and
Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
The term “diabodies” refers to small antibody fragments with two antigen-binding
sites, which fragments comprise a heavy chain variable domain (V ) connected to a light chain
variable domain (V ) in the same polypeptide chain (V - V ). By using a linker that is too short
L H L
to allow pairing between the two domains on the same chain, the domains are forced to pair with
the complementary domains of another chain and create two antigen-binding sites. Diabodies are
described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc.
Natl. Acad. Sci. USA, 90:6444-6448 (1993).
The term “multispecific antibody” is used in the broadest sense and specifically covers
an antibody that has polyepitopic specificity. Such multispecific antibodies include, but are not
limited to, an antibody comprising a heavy chain variable domain (V ) and a light chain variable
domain (V ), where the V V unit has polyepitopic specificity, antibodies having two or more
L H L
V and V domains with each V V unit binding to a different epitope, antibodies having two or
L H H L
more single variable domains with each single variable domain binding to a different epitope,
full length antibodies, antibody fragments such as Fab, Fv, dsFv, scFv, diabodies, bispecific
diabodies, triabodies, tri-functional antibodies, antibody fragments that have been linked
covalently or non-covalently. “Polyepitopic specificity” refers to the ability to specifically bind
to two or more different epitopes on the same or different target(s). “Monospecific” refers to the
ability to bind only one epitope. According to one embodiment the multispecific antibody is an
IgG antibody that binds to each epitope with an affinity of 5 mM to 0.001 pM, 3 mM to 0.001
pM, 1 mM to 0.001 pM, 0.5 mM to 0.001 pM, or 0.1 mM to 0.001 pM.
The expression “single domain antibodies” (sdAbs) or “single variable domain (SVD)
antibodies” generally refers to antibodies in which a single variable domain (VH or VL) can
confer antigen binding. In other words, the single variable domain does not need to interact with
another variable domain in order to recognize the target antigen. Examples of single domain
antibodies include those derived from camelids (lamas and camels) and cartilaginous fish (e.g.,
nurse sharks) and those derived from recombinant methods from humans and mouse antibodies
(Nature (1989) 341:544-546; Dev Comp Immunol (2006) 30:43-56; Trend Biochem Sci (2001)
26:230-235; Trends Biotechnol (2003):21:484-490; ; WO 03/035694; Febs
Lett (1994) 339:285-290; WO00/29004; WO 02/051870).
The term “monoclonal antibody” as used herein refers to an antibody obtained from a
population of substantially homogeneous antibodies, i.e., the individual antibodies comprising
the population are identical and/or bind the same epitope, except for possible variants that may
arise during production of the monoclonal antibody, such variants generally being present in
minor amounts. In contrast to polyclonal antibody preparations that typically include different
antibodies directed against different determinants (epitopes), each monoclonal antibody is
directed against a single determinant on the antigen. In addition to their specificity, the
monoclonal antibodies are advantageous in that they are uncontaminated by other
immunoglobulins. The modifier “monoclonal” indicates the character of the antibody as being
obtained from a substantially homogeneous population of antibodies, and is not to be construed
as requiring production of the antibody by any particular method. For example, the monoclonal
antibodies to be used in accordance with the methods provided herein may be made by the
hybridoma method first described by Kohler et al., Nature 256:495 (1975), or may be made by
recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The “monoclonal antibodies”
may also be isolated from phage antibody libraries using the techniques described in Clackson et
al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991), for example.
The monoclonal antibodies herein specifically include “chimeric” antibodies
(immunoglobulins) in which a portion of the heavy and/or light chain is identical with or
homologous to corresponding sequences in antibodies derived from a particular species or
belonging to a particular antibody class or subclass, while the remainder of the chain(s) is
identical with or homologous to corresponding sequences in antibodies derived from another
species or belonging to another antibody class or subclass, as well as fragments of such
antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567;
Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). Chimeric antibodies of
interest herein include “primatized” antibodies comprising variable domain antigen-binding
sequences derived from a non-human primate (e.g. Old World Monkey, such as baboon, rhesus
or cynomolgus monkey) and human constant region sequences (US Pat No. 5,693,780).
“Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies
that contain minimal sequence derived from non-human immunoglobulin. For the most part,
humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a
hypervariable region of the recipient are replaced by residues from a hypervariable region of a
non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the
desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of
the human immunoglobulin are replaced by corresponding non-human residues. Furthermore,
humanized antibodies may comprise residues that are not found in the recipient antibody or in
the donor antibody. These modifications are made to further refine antibody performance. In
general, the humanized antibody will comprise substantially all of at least one, and typically
two, variable domains, in which all or substantially all of the hypervariable loops correspond to
those of a non-human immunoglobulin and all or substantially all of the FRs are those of a
human immunoglobulin sequence, except for FR substitution(s) as noted above. The humanized
antibody optionally also will comprise at least a portion of an immunoglobulin constant region,
typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-
525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.
2:593-596 (1992).
For the purposes herein, an “intact antibody” is one comprising heavy and light
variable domains as well as an Fc region. The constant domains may be native sequence
constant domains (e.g. human native sequence constant domains) or amino acid sequence variant
thereof. Preferably, the intact antibody has one or more effector functions.
“Native antibodies” are usually heterotetrameric glycoproteins of about 150,000
daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each
light chain is linked to a heavy chain by one covalent disulfide bond, while the number of
disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each
heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain
has at one end a variable domain (V ) followed by a number of constant domains. Each light
chain has a variable domain at one end (V ) and a constant domain at its other end; the constant
domain of the light chain is aligned with the first constant domain of the heavy chain, and the
light chain variable domain is aligned with the variable domain of the heavy chain. Particular
amino acid residues are believed to form an interface between the light chain and heavy chain
variable domains.
A “naked antibody” is an antibody (as herein defined) that is not conjugated to a
heterologous molecule, such as a cytotoxic moiety or radiolabel.
In some embodiments, antibody “effector functions” refer to those biological activities
attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc
region) of an antibody, and vary with the antibody isotype. Examples of antibody effector
functions include: C1q binding and complement dependent cytotoxicity; Fc receptor binding;
antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell
surface receptors.
“Antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to a cell-mediated
reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (e.g. Natural
Killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and
subsequently cause lysis of the target cell. The primary cells for mediating ADCC, NK cells,
express Fc γRIII only, whereas monocytes express Fc γRI, Fc γRII and Fc γRIII. FcR expression
on hematopoietic cells in summarized is Table 3 on page 464 of Ravetch and Kinet, Annu. Rev.
Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC
assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful
effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural
Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may
be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al., Proc. Natl.
Acad. Sci. (USA) 95:652-656 (1998).
“Human effector cells” are leukocytes that express one or more FcRs and perform
effector functions. In some embodiments, the cells express at least Fc γRIII and carry out ADCC
effector function. Examples of human leukocytes that mediate ADCC include peripheral blood
mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and
neutrophils; with PBMCs and NK cells being preferred.
The terms “Fc receptor” or “FcR” are used to describe a receptor that binds to the Fc
region of an antibody. In some embodiments, the FcR is a native sequence human FcR.
Moreover, a preferred FcR is one that binds an IgG antibody (a gamma receptor) and includes
receptors of the Fc γRI, Fc γRII, and Fc γ RIII subclasses, including allelic variants and
alternatively spliced forms of these receptors. Fc γRII receptors include Fc γRIIA (an “activating
receptor”) and Fc γRIIB (an “inhibiting receptor”), which have similar amino acid sequences that
differ primarily in the cytoplasmic domains thereof. Activating receptor Fc γRIIA contains an
immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting
receptor Fc γRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its
cytoplasmic domain. (see Daëron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed
in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-
34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including
those to be identified in the future, are encompassed by the term “FcR” herein. The term also
includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to
the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).
The term “sequential” as used herein with regard to chromatography refers to having a
first chromatography followed by a second chromatography. Additional steps may be included
between the first chromatography and the second chromatography.
The term “continuous” as used herein with regard to chromatography refers to having a
first chromatography material and a second chromatography material either directly connected
or some other mechanism which allows for continuous flow between the two chromatography
materials.
“Contaminants” refer to materials that are different from the desired polypeptide
product. The contaminant includes, without limitation: host cell materials, such as CHOP;
leached Protein A; nucleic acid; a variant, fragment, aggregate or derivative of the desired
polypeptide; another polypeptide; endotoxin; viral contaminant; cell culture media component,
etc. In some examples, the contaminant may be a host cell protein (HCP) from, for example but
not limited to, a bacterial cell such as an E. coli cell, an insect cell, a prokaryotic cell, a
eukaryotic cell, a yeast cell, a mammalian cell, an avian cell, a fungal cell.
The “dynamic binding capacity” of a chromatography material is the amount of
product, e.g. polypeptide, the material will bind under actual flow conditions before significant
breakthrough of unbound product occurs.
“Partition coefficient”, K , as used herein, refers to the molar concentration of product,
e.g. polypeptide, in the stationary phase divided by the molar concentration of the product in the
mobile phase.
“Loading density” refers to the amount, e.g. grams, of composition put in contact with
a volume of chromatography material, e.g. liters. In some examples, loading density is
expressed in g/L.
Reference to “about” a value or parameter herein includes (and describes) variations
that are directed to that value or parameter per se. For example, description referring to “about
X” includes description of “X”.
As used herein and in the appended claims, the singular forms “a,” “or,” and “the”
include plural referents unless the context clearly dictates otherwise. It is understood that aspects
and variations of the invention described herein include “consisting” and/or “consisting
essentially of” aspects and variations.
II. Methods of Purification
Provided herein are methods for purifying a product, such as a polypeptide, from a
composition comprising the product and at least one contaminant using overload and elute
chromatography (OEC). OEC provides a mode of operation where benefits provided by
different modes of chromatography are realized within a single chromatography mode. OEC
can be implemented on multiple resins while providing enhanced impurity removal and
significant manufacturing advantages, such as smaller columns, better plant fit and lower cost.
The mode of operation with OEC can be broken down into three different components.
1. Overload – The composition is loaded onto the chromatography material such that
the product, e.g. a polypeptide, is loaded onto the chromatography material at an amount
exceeding the dynamic binding capacity (DBC) of the material for the product. In some
embodiments, loading conditions, such as pH and conductivity, are determined where impurities
strongly bind to the chromatography material. In some embodiments, the chromatography
conditions are chosen such that, even if product breaks through after binding most, if not all, of
the impurities do not. In some embodiments the composition is loaded at or near the DBC of the
material for the one or more contaminants. The overload mode allows the chromatography
material to be utilized beyond the typical DBC of the material for the product.
2. Pooling – The pooling of the product, e.g. a polypeptide, in the eluant starts at the
product breakthrough. Since the load conditions are such that impurities continue to bind during
the breakthrough phase, a clean product pool may be obtained in the eluant during the load
phase of chromatography.
3. Elution – Upon completion of loading of the composition on the chromatography
material, the product, e.g. polypeptide, is eluted from the chromatography material using elution
conditions that are identified such that bound product is eluted while majority of the impurities
remain bound to the chromatography material.
In some embodiments, OEC increases chromatography material utilization
significantly beyond the DBC of the material for the product thereby providing benefit
compared to other chromatography methods. For example, 10-fold higher chromatography
material utilization may result in significantly lower cost.
Unlike traditional bind and elute chromatography where loading of the
chromatography material is optimized to maximize binding to the product, e.g. polypeptide, to
the chromatography resin, with OEC load conditions may be optimized to maximize binding of
contaminants to the chromatography material and not binding of the product to the
chromatography material. In some embodiments, the composition is loaded onto a
chromatography material at an amount exceeding the dynamic binding capacity of the
chromatography material for the product. In the process of loading the chromatography
material, some of the product will break-through in the wash and some of the product will
remain bound to the chromatography material. Upon completion of load, the remaining product
bound to the chromatography material can be eluted from the chromatography material. In some
embodiments of the above, the chromatography material is a chromatography column. In some
embodiments of the above, the chromatography material is a chromatography membrane.
In some aspects of the invention, a composition is loaded onto a chromatography
material at about the dynamic binding capacity of the chromatography material for one or more
of the contaminants in the composition. In some embodiments, a composition is loaded onto a
chromatography material at an amount exceeding the binding capacity of the chromatography
material for the product. In some embodiments, a composition is loaded onto a chromatography
material at about the dynamic binding capacity of the chromatography material for one or more
of the contaminants and exceeding the binding capacity of the chromatography material for the
product. In some embodiments, the composition is loaded onto the chromatography material at
-times the DBC of the chromatography material for the product. In some embodiments, the
composition is loaded onto the chromatography material at 100-times the DBC of the
chromatography material for the product. In some embodiments, the composition is loaded onto
a chromatography material at about the dynamic binding capacity of the chromatography
material for all of the contaminants in the composition. In some embodiments, a composition is
loaded onto a chromatography material at about the dynamic binding capacity of the
chromatography material for all of the contaminants and exceeding the binding capacity of the
chromatography material for the product. In some embodiments, a composition is loaded onto a
chromatography material at less than the dynamic binding capacity of the chromatography
material for all of the contaminants and exceeding the binding capacity of the chromatography
material for the product. In some embodiments of the above, the chromatography material is in a
chromatography column. In some embodiments, the chromatography column is an industrial
scale chromatography column. In some embodiments of the above, the chromatography
material is a chromatography membrane.
The dynamic binding capacity of a chromatography material for a product and for one
or more contaminants can be estimated by determining the partition coefficient (K ) for the
product or contaminants as a function of pH and counterion concentration for a particular
chromatography material. For example, the dynamic binding capacity of a chromatography
material, e.g. a mixed mode resin, for a polypeptide may be determined. Actual binding
capacities of a chromatography material for a product or contaminant at a specific combination
of pH and counterion concentration can be determined by challenging the binding with an excess
of the product and/or contaminant.
In some embodiments, the OEC is performed where the K of the product, e.g.
polypeptide, is greater than about 30. In some embodiments, the OEC is performed where the
K of the product is greater than about 50. In some embodiments, the OEC is performed where
the K of the product is greater than about 75. In some embodiments, the OEC is performed
where the K of the product is greater than about 100.
The conditions for OEC of a particular composition comprising a product, such as a
polypeptide, and contaminant can be determined by measuring the K and dynamic binding
capacity of particular chromatography material at different pH and counterion concentration.
High throughput screening can be conducted to determine OEC conditions where binding of
contaminants is high and where the product may be eluted without eluting most if not all of the
contaminants. For example, the composition can be incubated with a chromatography material
in buffer at various pH and counterion concentrations under high throughput system; for
example, in wells of a multiple-well plate. After an incubation period, the supernatant is
separated from the chromatography material and the amount of product or contaminant in the
supernatant is determined. In some embodiments, low concentrations of composition are used to
determine K . In some embodiments, high concentrations of the composition are used to
determine dynamic binding capacities.
In addition to providing information regarding K and dynamic binding capacity of a
chromatography material for particular products and contaminants, high throughput screening
provides guidance to load and elute conditions in terms of pH and counterion concentration. For
example, in some embodiments, the load buffer is selected by high throughput screening for a
pH and counterion concentration to maximize contaminant binding to the chromatography
material but to also to maximize the amount of product, e.g. polypeptide, in the eluent while
minimizing the amount of contaminant, e.g. host cell protein, in the eluent. In some
embodiments, the composition is loaded onto a chromatography material at a pH and
conductivity determined by high throughput screening wherein about all of the contaminants in
the composition bind to the chromatography material. In some embodiments, the product is
eluted from the chromatography material at a pH and conductivity determined by high
throughput screening wherein about all of the product elutes from the chromatography material
and about all of the contaminants remain bound to the chromatography material.
In some embodiments, described are methods for identifying the operating conditions
(e.g. by using high throughput screening techniques) that cause the chromatography material to
bind a maximum amount of contaminants irrespective of the amount of product bound per mL of
chromatography material. The screening step is used to identify the elution conditions such that
the bound product is eluted from the chromatography material and impurities remain tightly
bound to the chromatography material.
In some embodiments of any of the methods described herein, the chromatography
material is a mixed mode material comprising functional groups capable of one of more of the
following functionalities: anionic exchange, cation exchange, hydrogen bonding, and
hydrophobic interactions. In some embodiments, the mixed mode material comprises functional
groups capable of anionic exchange and hydrophobic interactions. The mixed mode material
may contain N-benzyl-N-methyl ethanol amine, 4-mercapto-ethyl-pyridine, hexylamine, or
phenylpropylamine as ligand or contain cross-linked polyallylamine. Examples of the mixed
mode materials include Capto Adhere resin, QMA resin, Capto MMC resin, MEP HyperCel
resin, HEA HyperCel resin, PPA HyperCel resin, or ChromaSorb membrane or Sartobind STIC.
In some embodiments, the mixed mode material is Capto Adhere resin. In some embodiments
of the above, the mixed mode material is a mixed mode chromatography column. In some
embodiments of the above, the mixed mode material is a mixed mode membrane.
In some embodiments of any of the methods described herein, the chromatography
material is an ion exchange chromatography material; for example, an anion exchange
chromatography material or a cation exchange chromatography material. In some embodiments
of any of the methods described herein, the chromatography material is an anion exchange
material. In some embodiments, the anion exchange chromatography material is a solid phase
that is positively charged and has free anions for exchange with anions in an aqueous solution
passed over or through the solid phase. In some embodiments of any of the methods described
herein, the anion exchange material may be a membrane, a monolith, or resin. In an
embodiment, the anion exchange material may be a resin. In some embodiments, the anion
exchange material may comprise a primary amine, a secondary amine, a tertiary amine or a
quarternary ammonium ion functional group, a polyamine functional group, or a
diethylaminoaethyl functional group. In some embodiments of the above, the anion exchange
chromatography material is an anion exchange chromatography column. In some embodiments
of the above, the anion exchange chromatography material is an anion exchange
chromatography membrane.
In some embodiments of any of the methods described herein, the chromatography
material is a cation exchange material. In some embodiments, the cation exchange material is a
solid phase that is negatively charged and has free cations for exchange with cations in an
aqueous solution passed over or through the solid phase. In some embodiments of any of the
methods described herein, the cation exchange material may be a membrane, a monolith, or
resin. In some embodiments, the cation exchange material may be a resin. The cation exchange
material may comprise a carboxylic acid functional group or a sulfonic acid functional group
such as, but not limited to, sulfonate, carboxylic, carboxymethyl sulfonic acid, sulfoisobutyl,
sulfoethyl, carboxyl, sulphopropyl, sulphonyl, sulphoxyethyl, or orthophosphate. In some
embodiments of the above, the cation exchange chromatography material is a cation exchange
chromatography column. In some embodiments of the above, the cation exchange
chromatography material is a cation exchange chromatography membrane. In some
embodiments, the chromatography material is not a cation exchange chromatography material.
In some embodiments of any of the methods described herein, the ion exchange
material may utilize a conventional chromatography material or a convective chromatography
material. The conventional chromatography materials include, for example, perfusive materials
(e.g., poly (styrene-divinylbenzene) resin) and diffusive materials (e.g., cross-linked agarose
resin). In some embodiments, the poly (styrene-divinylbenzene) resin can be Poros resin. In
some embodiments, the cross-linked agarose resin may be sulphopropyl-Sepharose Fast Flow
("SPSFF") resin. The convective chromatography material may be a membrane (e.g.,
polyethersulfone) or monolith material (e.g. cross-linked polymer). The polyethersulfone
membrane may be Mustang. The cross-linked polymer monolith material may be cross-linked
poly(glycidyl methacrylate-co-ethylene dimethacrylate).
Examples of anion exchange materials are know in the art and include, but are not
limited to Poros HQ 50, Poros PI 50, Poros D, Mustang Q, Q Sepharose FF, and DEAE
Sepharose.
Examples of cation exchange materials are known in the art include, but are not limited
to Mustang S, Sartobind S, SO3 Monolith, S Ceramic HyperD, Poros XS, Poros HS50, Poros
HS20, SPSFF, SP-Sepharose XL (SPXL), CM Sepharose Fast Flow, Capto S, Fractogel Se
HiCap, Fractogel SO3, or Fractogel COO. In some embodiments of any of the methods
described herein, the cation exchange material is Poros HS50. In some embodiments, the Poros
HS resin may be Poros HS 50 µm or Poros HS 20 µm particles.
In some aspects of the invention, the chromatography material is a hydrophobic
interaction chromatography material. Hydrophobic interaction chromatography (HIC) is a liquid
chromatography technique that separates biomolecules according to hydrophobicity. Examples
of HIC chromatography materials include, but are not limited to, Toyopearl hexyl 650, Toyopear
butyl 650, Toyopearl phenyl 650, Toyopearl ether 650, Source, Resource, Sepharose Hi-Trap,
Octyl sepharose, Phenyl sepharose. In some embodiments of the above, the HIC
chromatography material is a HIC chromatography column. In some embodiments of the above,
the HIC chromatography material is a HIC chromatography membrane.
In some embodiments, the chromatography material is a hydroxyapatite (HAP)
chromatography material. Examples of hydroxyapatite chromatography material include but are
limited to HA Ultrogel, and CHT hydroxyapatite. In some embodiments of the above, the HAP
chromatography material is a HAP chromatography column. In some embodiments of the
above, the HAP chromatography material is a HAP chromatography membrane.
In some aspects of the invention, the chromatography material is an affinity
chromatography material. Examples of affinity chromatography materials include, but are not
limited to chromatography materials derivatized with protein A or protein G. Examples of
affinity chromatography material include, but are not limited to, Prosep-VA, Prosep-VA Ultra
Plus, Protein A sepharose fast flow, Tyopearl Protein A, MAbSelect, MAbSelect SuRe and
MAbSelect SuRe LX. In some embodiments of the above, the affinity chromatography material
is an affinity chromatography column. In some embodiments of the above, the affinity
chromatography material is an affinity chromatography membrane.
Loading of the composition on the chromatography material may be optimized for
separation of the product from contaminants by OEC. In some embodiments, the product is a
polypeptide. In some embodiments, loading on the composition onto the chromatography
material is optimized for binding of the contaminants to the chromatography material. For
example, the composition may be loaded onto the chromatography material, e.g. a
chromatography column, in a load buffer at a number of different pH while the conductivity of
the load buffer is constant. Alternatively, the composition may be loaded onto the
chromatography material in a load buffer at a number of different conductivities while the pH of
the load buffer is constant. Upon completion of loading the composition on the chromatography
material and elution of the product from the chromatography material into a pool fraction, the
amount of contaminant in the pool fraction provides information regarding the separation of the
product from the contaminants for a given pH or conductivity. In some embodiments of any of
the methods described herein, the composition is loaded onto a chromatography material at a
loading density of the polypeptide of greater than about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70
g/L, 80 g/L, 90 g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180
g/L, 190 g/L, 200 g/L, 300 g/L, 400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L,
900 g/L, 1000 g/L, 2000 g/L or 5000 g/L of the chromatography material. In some
embodiments, the composition is loaded onto a chromatography material at a loading density of
the polypeptide of about any of about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90
g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L,
200 g/L, 300 g/L, 400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000
g/L or 2000 g/L of the chromatography material. The composition may be loaded onto a
chromatography material at a loading density of the polypeptide of between about any of 30 g/L
and 2000 g/L, 30 g/L and 1000 g/L, 30 g/L and 200 g/L, 30 g/L and 180 g/L, 50 g/L and 2000
g/L, 50 g/L and 1000 g/L, 50 g/L and 200 g/L, 50 g/L and 180 g/L, 150 g/L and 2000 g/L, 150
g/L and 1500 g/L, 150 g/L and 1000 g/L, 200 g/L and 1000 g/L, 200 g/L and 1500 g/L, 300 g/L
and 1500 g/L, 400 g/L and 1000 g/L, or 500 g/L and 1000 g/L of chromatography material.
In some embodiments of any of the methods described herein, the composition is
loaded onto a mixed mode chromatography material at a loading density of the polypeptide of
greater than about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, 100 g/L, 110
g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, 200 g/L, 300 g/L,
400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000 g/L, 2000 g/L or
5000 g/L of the mixed mode chromatography material. In some embodiments, the composition
is loaded onto a mixed mode chromatography material at a loading density of the polypeptide of
about any of about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, 100 g/L, 110
g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, 200 g/L, 300 g/L,
400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000 g/L or 2000 g/L of
the mixed mode chromatography material. The composition may be loaded onto a mixed mode
chromatography material at a loading density of the polypeptide of between about any of 30 g/L
and 2000 g/L, 30 g/L and 1000 g/L, 30 g/L and 200 g/L, 30 g/L and 180 g/L, 50 g/L and 2000
g/L, 50 g/L and 1000 g/L, 50 g/L and 200 g/L, 50 g/L and 180 g/L, 150 g/L and 2000 g/L, 150
g/L and 1500 g/L, 150 g/L and 1000 g/L, 200 g/L and 1000 g/L, 200 g/L and 1500 g/L, 300 g/L
and 1500 g/L, 400 g/L and 1000 g/L, or 500 g/L and 1000 g/L of mixed mode chromatography
material. In some embodiments, the polypeptide is loaded on a chromatography material at a
density of 70 g/L to 180 g/L. In some embodiments, the mixed mode chromatography is a
Capto Adhere resin. In some embodiments, the polypeptide is loaded on a Capto Adhere
chromatography material at a density of 70 g/L to 180 g/L. In further embodiments of the above
embodiments, the polypeptide is an antibody of a fragment thereof.
In some embodiments of any of the methods described herein, the composition is
loaded onto an anion exchange chromatography material at a loading density of the polypeptide
of greater than about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, 100 g/L, 110
g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, 200 g/L, 300 g/L,
400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000 g/L, 2000 g/L or
5000 g/L of the anion exchange chromatography material. In some embodiments, the
composition is loaded onto an anion exchange chromatography material at a loading density of
the polypeptide of about any of about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90
g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L,
200 g/L, 300 g/L, 400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000
g/L or 2000 g/L of the an anion exchange chromatography material. The composition may be
loaded onto an anion exchange chromatography material at a loading density of the polypeptide
of between about any of 30 g/L and 2000 g/L, 30 g/L and 1000 g/L, 30 g/L and 200 g/L, 30 g/L
and 180 g/L, 50 g/L and 2000 g/L, 50 g/L and 1000 g/L, 50 g/L and 200 g/L, 50 g/L and 180
g/L, 150 g/L and 2000 g/L, 150 g/L and 1500 g/L, 150 g/L and 1000 g/L, 200 g/L and 1000 g/L,
200 g/L and 1500 g/L, 300 g/L and 1500 g/L, 400 g/L and 1000 g/L, or 500 g/L and 1000 g/L of
the anion exchange chromatography material.
In some embodiments of any of the methods described herein, the composition is
loaded onto a cation exchange chromatography material at a loading density of the polypeptide
of greater than about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, 100 g/L, 110
g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, 200 g/L, 300 g/L,
400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000 g/L, 2000 g/L or
5000 g/L of the cation exchange chromatography material. In some embodiments, the
composition is loaded onto a cation exchange chromatography material at a loading density of
about any of about any of 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, 100 g/L, 110
g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, 200 g/L, 300 g/L,
400 g/L, 500 g/L, 550 g/L, 600 g/L, 650 g/L, 700 g/L, 800 g/L, 900 g/L, 1000 g/L or 2000 g/L of
the cation exchange chromatography material. The composition may be loaded onto a cation
exchange chromatography material at a loading density of the polypeptide of between about any
of 30 g/L and 2000 g/L, 30 g/L and 1000 g/L, 30 g/L and 200 g/L, 30 g/L and 180 g/L, 50 g/L
and 2000 g/L, 50 g/L and 1000 g/L, 50 g/L and 200 g/L, 50 g/L and 180 g/L, 150 g/L and 2000
g/L, 150 g/L and 1500 g/L, 150 g/L and 1000 g/L, 200 g/L and 1000 g/L, 200 g/L and 1500 g/L,
300 g/L and 1500 g/L, 400 g/L and 1000 g/L, or 500 g/L and 1000 g/L of the cation exchange
chromatography material.
The methods described above may further comprise the step of loading onto a Protein
A affinity chromatography material. In some embodiments the polypeptide product is an
antibody or fragment thereof that is first purified by Protein A affinity chromatography prior to
OEC. The step of loading onto a Protein A affinity chromatography material is generally, but
not necessarily, performed before the other chromatography step(s). In some embodiments, the
step of loading onto a Protein A affinity chromatography material may be combined with the
sequential steps of overloaded exchange and elute chromatography. In some embodiments, the
sequential steps are continuous. In some embodiments, the continuous purification utilizes the
same flow rate, conductivity, and/or pH.
Elution of the product such as a polypeptide from the chromatography material under
OEC mode may be optimized for yield of product with minimal contaminants and at minimal
pool volume. For example, the composition may be loaded onto the chromatography material,
e.g. a chromatography column, in a load buffer. Upon completion of load, the product is eluted
with buffers at a number of different pH while the conductivity of the elution buffer is constant.
Alternatively, the product may be eluted from the chromatography material in an elution buffer
at a number of different conductivities while the pH of the elution buffer is constant. Upon
completion of elution of the product from the chromatography material, the amount of
contaminant in the pool fraction provides information regarding the separation of the product
from the contaminants for a given pH or conductivity. Elution of the product in a high number
of fractions (e.g. eight column volumes) indicates “tailing” of the elution profile. In some
embodiments, tailing of the elution is minimized.
Various buffers which can be employed depending, for example, on the desired pH of
the buffer, the desired conductivity of the buffer, the characteristics of the protein of interest, and
the purification method. In some embodiments of any of the methods described herein, the
methods comprise using a buffer. The buffer can be a loading buffer, an equilibration buffer, or
a wash buffer. In some embodiments, one or more of the loading buffer, the equilibration buffer,
and/or the wash buffer are the same. In some embodiments, the loading buffer, the equilibration
buffer, and/or the wash buffer are different. In some embodiments of any of the methods
described herein, the buffer comprises a salt. The loading buffer may comprise sodium chloride,
sodium acetate, or a mixture thereof. In some embodiments, the loading buffer is a sodium
chloride buffer. In some embodiments, the loading buffer is a sodium acetate buffer.
Load, as used herein, is the composition loaded onto a chromatography material.
Loading buffer is the buffer used to load the composition comprising the product of interest onto
a chromatography material. The chromatography material may be equilibrated with an
equilibration buffer prior to loading the composition which is to be purified. In some examples,
the wash buffer is used after loading the composition onto a chromatography material and before
elution of the polypeptide of interest from the solid phase. However, some of the product of
interest, e.g. a polypeptide, may be removed from the chromatography material by the wash
buffer (e.g. similar to a flow-through mode).
Elution, as used herein, is the removal of the product, e.g. polypeptide, from the
chromatography material. Elution buffer is the buffer used to elute the polypeptide or other
product of interest from a chromatography material. In many cases, an elution buffer has a
different physical characteristic than the load buffer. For example, the elution buffer may have a
different conductivity than load buffer or a different pH than the load buffer. In some
embodiments, the elution buffer has a lower conductivity than the load buffer. In some
embodiments, the elution buffer has a higher conductivity than the load buffer. In some
embodiments, the elution buffer has a lower pH than the load buffer. In some embodiments, the
elution buffer has a higher pH than the load buffer. In some embodiments the elution buffer has
a different conductivity and a different pH than the load buffer. The elution buffer can have any
combination of higher or lower conductivity and higher or lower pH.
Conductivity refers to the ability of an aqueous solution to conduct an electric current
between two electrodes. In solution, the current flows by ion transport. Therefore, with an
increasing amount of ions present in the aqueous solution, the solution will have a higher
conductivity. The basic unit of measure for conductivity is the Siemen (or mho), mho (mS/cm),
and can be measured using a conductivity meter, such as various models of Orion conductivity
meters. Since electrolytic conductivity is the capacity of ions in a solution to carry electrical
current, the conductivity of a solution may be altered by changing the concentration of ions
therein. For example, the concentration of a buffering agent and/or the concentration of a salt
(e.g. sodium chloride, sodium acetate, or potassium chloride) in the solution may be altered in
order to achieve the desired conductivity. Preferably, the salt concentration of the various
buffers is modified to achieve the desired conductivity.
In some embodiments of any of the methods described herein, the load buffer has a
conductivity of greater than about any of 4.0 mS/cm, 4.5 mS/cm, 5.0 mS/cm, 5.5 mS/cm, 6.0
mS/cm, 6.5 mS/cm, 7.0 mS/cm, 7.5 mS/cm, 8.0 mS/cm, 8.5 mS/cm, 9.0 mS/cm, 9.5 mS/cm, or
mS/cm. The conductivity may be between about any of 4 mS/cm and 17 mS/cm, 4 mS/cm
and 10 mS/cm, 4 mS/cm and 7 mS/cm, 5 mS/cm and 17 mS/cm, 5 mS/cm and 10 mS/cm, or 5
mS/cm and 7 mS/cm. In some embodiments, the conductivity is about any of 4 mS/cm, 4.5
mS/cm, 5.0 mS/cm, 5.5 mS/cm, 6.0 mS/cm, 6.5 mS/cm, 7.0 mS/cm, 7.5 mS/cm, 8.0 mS/cm, 8.5
mS/cm, 9.0 mS/cm, 9.5 mS/cm, or 10 mS/cm. In one embodiment, the conductivity is the
conductivity of the loading buffer, the equilibration buffer, and/or the wash buffer. In some
embodiments, the conductivity of one or more of the loading buffer, the equilibration buffer, and
the wash buffer are the same. In some embodiments, the conductivity of the loading buffer is
different from the conductivity of the wash buffer and/or equilibration buffer. In some
embodiments, the composition is loaded on a mixed mode chromatography material in a buffer
with a conductivity of about 5.5 mS/cm. In some embodiments, the polypeptide is an antibody
or fragment thereof.
In some embodiments, the elution buffer has a conductivity less than the conductivity
of the load buffer. In some embodiments of any of the methods described herein, the elution
buffer has a conductivity of less than about any of 0.0 mS/cm, 0.5 mS/cm, 1.0 mS/cm, 1.5
mS/cm, 2.0 mS/cm, 2.5 mS/cm, 3.0 mS/cm, 3.5 mS/cm, 4.0 mS/cm, 4.5 mS/cm, 5.0 mS/cm, 5.5
mS/cm, 6.0 mS/cm, 6.5 mS/cm, or 7.0 mS/cm. The conductivity may be between about any of 0
mS/cm and 7 mS/cm, 1 mS/cm and 7 mS/cm, 2 mS/cm and 7 mS/cm, 3 mS/cm and 7 mS/cm, or
4 mS/cm and 7 mS/cm, 0 mS/cm and 5.0 mS/cm, 1 mS/cm and 5 mS/cm, 2 mS/cm and 5
mS/cm, 3 mS/cm and 5 mS/cm, or 4 mS/cm and 5 mS/cm. In some embodiments, the
conductivity of the elution buffer is about any of 0.0 mS/cm, 0.5 mS/cm, 1.0 mS/cm, 1.5 mS/cm,
2.0 mS/cm, 2.5 mS/cm, 3.0 mS/cm, 3.5 mS/cm, 4 mS/cm, 4.5 mS/cm, 5.0 mS/cm, 5.5 mS/cm,
6.0 mS/cm, 6.5 mS/cm, or 7.0 mS/cm. In some embodiments, the elution buffers described
above are used in mixed mode OEC, anion exchange OEC, cation exchange OEC, affinity OEC
or HIC OEC.
In some embodiments, the elution buffer has a conductivity greater than the
conductivity of the load buffer. In some embodiments of any of the methods described herein,
the elution buffer has a conductivity of greater than about any of 5.5 mS/cm, 6.0 mS/cm, 6.5
mS/cm, 7.0 mS/cm, 7.5 mS/cm, 8.0 mS/cm, 8.5 mS/cm, 9.0 mS/cm, 9.5 mS/cm, 10 mS/cm, 11
mS/cm, 12 mS/cm, 13 mS/cm, 14 mS/cm, 15 mS/cm, 16 mS/cm, 17.0 mS/cm, 18.0 mS/cm, 19.0
mS/cm, 20.0 mS/cm, 21.0 mS/cm, 22.0 mS/cm, 23.0 mS/cm, 24.0 mS/cm, or 25.0 mS/cm. The
conductivity may be between about any of 5.5 mS/cm and 17 mS/cm, 6.0 mS/cm and 17 mS/cm,
7 mS/cm and 17 mS/cm, 8 mS/cm and 17 mS/cm, 9 mS/cm and 17 mS/cm, or 10 mS/cm and 17
mS/cm. In some embodiments, the conductivity of the elution buffer is about any of 5.5 mS/cm,
6.0 mS/cm, 6.5 mS/cm, 7.0 mS/cm, 7.5 mS/cm, 8.0 mS/cm, 8.5 mS/cm, 9.0 mS/cm, 9.5 mS/cm,
mS/cm, 11 mS/cm, 12 mS/cm, 13 mS/cm, 14 mS/cm, 15 mS/cm, 16 mS/cm, or 17.0 mS/cm.
In some embodiments, the elution buffers described above are used in mixed mode OEC, anion
exchange OEC, cation exchange OEC, an affinity OEC, or HIC OEC. In some embodiments,
the polypeptide is eluted from a mixed mode chromatography at a conductivity of about 4 to
about 1 mS/cm. In some embodiments, the polypeptide is eluted from a Capto Adhere
chromatography at a conductivity of about 4 to about 1 mS/cm. In some embodiments, an
antibody or fragment thereof is eluted form a Capto Adhere chromatography at a conductivity of
about 4 mS/cm to about 1 mS/cm.
In some of any of the above embodiments, the conductivity of the elution buffer
changed from the load and/or wash buffer by step gradient or by linear gradient.
In some embodiments, the composition comprising a polypeptide is loaded onto the
chromatography material in a buffer with a conductivity of about 5.5 mS/cm and the polypeptide
is eluted from the chromatography material in an elution buffer with a conductivity of about 4
mS/cm. In some embodiments, the load buffer has a conductivity of about 5.5 mS/cm and the
elution buffer has a conductivity of about 3 mS/cm. In some embodiments, the load buffer has a
conductivity of about 5.5 mS/cm and the elution buffer has a conductivity of about 2 mS/cm. In
some embodiments, the load buffer has a conductivity of about 5.5 mS/cm and the elution buffer
has a conductivity of about 1 mS/cm. In further embodiments of the above embodiments, the
chromatography material is a Capto Adhere resin. In further embodiments of the above
embodiments, the polypeptide is an antibody of fragment thereof.
In some embodiments of any of the above embodiments, the conductivity of the elution
buffer changed from the load and/or wash buffer by step gradient or by linear gradient. In some
embodiments, the composition comprising a polypeptide is loaded onto a Capto Adhere
chromatography at about 5.5 mS/cm and the polypeptide of interest is eluted from a Capto
Adhere Chromatography by a linear conductivity gradient from about 5.5 mS/cm to about 1
mS/cm over about 5 column volumes (CV). In some embodiments, the composition comprising
a polypeptide is loaded onto a Capto Adhere chromatography at about 5.5 mS/cm and the
polypeptide of interest is eluted from a Capto Adhere Chromatography by a linear conductivity
gradient from about 5.5 mS/cm to about 1mS/cm over 10.0 CV. In some embodiments, the
composition comprising a polypeptide is loaded onto a Capto Adhere chromatography at about
mS/cm and the polypeptide of interest is eluted from a Capto Adhere chromatography by a
linear conductivity gradient from about 10.0 mS/cm to about 1mS/cm over about 5 CV. In some
embodiments, the composition comprising a polypeptide is loaded onto a Capto Adhere
chromatography at about 10 mS/cm and the polypeptide of interest is eluted from a Capto
Adhere chromatography by a linear conductivity gradient from about 10.0 mS/cm to 1 mS/cm
over about 10 CV. In some embodiments, the composition comprising a polypeptide is loaded
onto a Capto Adhere chromatography at about 10 mS/cm and the polypeptide of interest is
eluted from a Capto Adhere chromatography by a linear conductivity gradient from about 10.0
mS/cm to abut 1mS/cm over about 15 CV.
In some embodiments of any of the above embodiments, the conductivity of the elution
buffer changed from the load and/or wash buffer by step gradient or by linear gradient. In some
embodiments, the composition comprising a polypeptide is loaded onto a chromatography
material at about 5.5mS/cm and the polypeptide of interest is eluted from a Chromatography
material by a linear conductivity gradient between 5.5 mS/cm to 1mS/cm over 5 Column
Volumes, 5.5 mS/cm to 1mS/cm over 10.0 Column Volumes. In some embodiments, the
composition comprising a polypeptide is loaded onto a chromatography material at about 10
mS/cm and the polypeptide of interest is eluted from a Chromatography material by a linear
conductivity gradient between 10.0 mS/cm to 1mS/cm over 5 Column Volumes, 10.0 mS/cm to
1 mS/cm over 10 Column Volumes, 10.0 mS/cm to 1mS/cm over 15 Column Volumes.
In some embodiments of any of the methods described herein, the load buffer has a pH
of less than about any of 10, 9, 8, 7, 6, or 5. In some embodiments of any of the methods
described herein, the load buffer has a pH of greater than about any of 4, 5, 6, 7, 8, or 9. The
load buffer may have a pH of between about any of 4 and 9, 4 and 8, 4 and 7, 5 and 9, 5 and 8, 5
and 7, 5 and 6. In some embodiments, the pH of the load buffer is about any of 4, 4.5, 5, 5.5, 6,
6.5, 7, 7.5, or 8. The pH can be the pH of the loading buffer, the equilibration buffer, or the wash
buffer. In some embodiments, the pH of one or more of the loading buffer, the equilibration
buffer, and/or the wash buffer are the same. In some embodiments, the pH of the loading buffer
is different from the pH of the equilibration buffer and/or the wash buffer.
In some embodiments, the elution buffer has a pH less than the pH of the load buffer.
In some embodiments of any of the methods described herein, the elution buffer has a pH of less
than about any of 8, 7, 6, 5, 4, 3 or 2. The pH of the elution buffer may be between about any of
4 and 9, 4 and 8, 4 and 7, 4 and 6, 4 and 5, 5 and 9, 5 and 8, 5 and 7, 5 and 6, 6 and 9, 6 and 8, 6
and 7. In some embodiments, the pH of the elution buffer is about any of 4.0, 4.5, 5.0. 5.5, 6.0,
6.5, 7/0, 7.5, 8.0, 8.5 or 9.0.
In some embodiments, the elution buffer has a pH greater than the pH of the load
buffer. In some embodiments of any of the methods described herein, the elution buffer has a
pH of greater than about any of 5, 6, 7, 8, or 9. The pH of the elution buffer may be between
about any of 4 and 9, 5 and 9, 6 and 9, 7 and 9, 8 and 9, 4 and 8, 5 and 8, 6 and 8, 7 and 8, 4 and
7, 5 and 7, and 6 and 7. In some embodiments, the pH of the elution buffer is about any of 4.0,
4.5, 5.0. 5.5, 6.0, 6.5, 7/0, 7.5, 8.0, 8.5 or 9.0
In some embodiments of any of the above embodiments, the pH of the elution buffer
changed from the load and/or wash buffer by step gradient or by linear gradient.
In some embodiments of any of the methods described herein, the flow rate is less than
about any of 50 CV/hr, 40 CV/hr, or 30 CV/hr. The flow rate may be between about any of 5
CV/hr and 50 CV/hr, 10 CV/hr and 40 CV/hr, or 18 CV/hr and 36 CV/hr. In some embodiments,
the flow rate is about any of 9 CV/hr, 18 CV/hr, 25 CV/hr, 30 CV/hr, 36 CV/hr, or 40 CV/hr. In
some embodiments of any of the methods described herein, the flow rate is less than about any
of 100 cm/hr, 75 cm/hr, or 50 cm/hr. The flow rate may be between about any of 25 cm/hr and
150 cm/hr, 25 cm/hr and 100 cm/hr, 50 cm/hr and 100 cm/hr, or 65 cm/hr and 85 cm/hr.
Bed height is the height of chromatography material used. In some embodiments of
any of the method described herein, the bed height is greater than about any of 3 cm, 10 cm, or
cm. The bed height may be between about any of 3 cm and 35 cm, 5 cm and 15 cm, 3 cm and
cm, or 5 cm and 8 cm. In some embodiments, the bed height is about any of 3 cm, 5 cm, 10
cm, or 15 cm. In some embodiments, bed height is determined based on the amount of
polypeptide or contaminants in the load.
In some embodiments, the chromatography is in a column of vessel with a volume of
greater than about 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, 15 mL, 20
mL, 25 mL, 30 mL, 40 mL, 50 mL, 75 mL, 100 mL, 200 mL, 300 mL, 400 mL, 500 mL, 600
mL, 700 mL, 800 mL, 900 mL, 1 L, 2 L, 3 L, 4 L, 5 L, 6 L, 7 L, 8 L, 9 L, 10 L, 25 L, 50 L, 100
L, 200 L, 300 L, 400 L, 500 L, 600 L, 700 L, 800 L, 900 L or 100 L.
In some embodiments of the invention, fractions are collected from the
chromatography. In some embodiments, fractions collected are greater than about 0.01 CV,
0.02 CV, 0.03 CV, 0.04 CV, 0.05 CV, 0.06 CV, 0.07 CV, 0.08 CV, 0.09 CV, 0.1 CV, 0.2 CV,
0.3 CV, 0.4 CV, 0.5 CV, 0.6 CV, 0.7 CV, 0.8 CV, 0.9 CV, 1.0 CV, 2.0 CV, 3.0 CV, 4.0 CV, 5.0
CV, 6.0 CV, 7.0 CV, 8.0 CV, 9.0 CV, or 10.0 CV. In some embodiments, fractions containing
the product, e.g. polypeptide, are pooled. In some embodiments, fractions containing the
polypeptide from the load fractions and from the elution fractions are pooled. The amount of
polypeptide in a fraction can be determined by one skilled in the art; for example, the amount of
polypeptide in a fraction can be determined by UV spectroscopy. In some embodiments,
fractions containing detectable polypeptide fragment are pooled.
In some embodiments of any of the methods described herein, the at least one
contaminant is any one or more of host cell materials, such as CHOP; leached Protein A; nucleic
acid; a variant, fragment, aggregate or derivative of the desired polypeptide; another
polypeptide; endotoxin; viral contaminant; cell culture media component, carboxypeptidase B,
gentamicin, etc. In some examples, the contaminant may be a host cell protein (HCP) from, for
example but not limited to, a bacterial cell such as an E. coli cell, an insect cell, a prokaryotic
cell, a eukaryotic cell, a yeast cell, a mammalian cell, an avian cell, a fungal cell.
Host cell proteins (HCP) are proteins from the cells in which the polypeptide was
produced. For example, CHOP are proteins from host cells, i.e., Chinese Hamster Ovary
Proteins. The amount of CHOP may be measured by enzyme-linked immunosorbent assay
(“ELISA”) or Meso Scale Discovery (“MSO”). In some embodiments of any of the methods
described herein, the amount of HCP (e.g. CHOP) is reduced by greater than about any of 10 %,
%, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, or 95 %. The amount of HCP may be
reduced by between about any of 10 % and 99 %, 30% and 95%, 30 % and 99 %, 50% and 95%,
50 % and 99 %, 75 % and 99 %, or 85 % and 99 %. In some embodiments, the amount of HCP
is reduced by about any of 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 85 %, 90 %, 95
%, or 98 %. In some embodiments, the reduction is determined by comparing the amount of
HCP in the composition recovered from a purification step(s) to the amount of HCP in the
composition before the purification step(s).
Aggregated polypeptide can be high molecular weight (HMW) protein. In some
embodiments, the aggregated polypeptide is multimers of the polypeptide of interest. The HMW
protein may be a dimer, up to 8x monomer, or larger of the polypeptide of interest. Methods of
measuring aggregated protein (e.g., HMW protein) are known in the art and described in the
examples section. In some embodiments of any of the methods described herein, the amount of
aggregated protein is reduced by greater than about any of 5%, 10 %, 20 %, 30 %, 40 %, 50 %,
60 %, 70 %, 80 %, 90 %, or 95 %. The amount of aggregated protein may be reduced by
between about any of 10 % and 99 %, 30% and 95%, 30 % and 99 %, 50% and 95%, 50 % and
99 %, 75 % and 99 %, or 85 % and 99 %. The amount of aggregated protein may be reduced by
about any of 5 %, 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, or 95 %. In some
embodiments, the reduction is determined by comparing the amount of aggregated protein (e.g.,
HMW protein) in the composition recovered from a purification step(s) to the amount of
aggregated protein (e.g., HMW protein) in the composition before the purification step(s).
Fragment polypeptide can be low molecular weight (LMW) protein. In some
embodiments, the fragmented polypeptide is a fragment of the polypeptide of interest. Examples
of LMW protein include, but not limited to, a Fab (Fragment antigen binding), Fc (fragment,
crystallizable) regions or combination of both or any random fragmented part of an antibody of
interest. Methods of measuring fragmented protein (e.g., LMW protein) are known in the art and
described in the examples section. In some embodiments of any of the methods described
herein, the amount of LMW protein is reduced by greater than about any of 5%, 10 %, 20 %, 30
%, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, or 95 %. The amount of LMW protein may be reduced
by between about any of 10 % and 99 %, 30% and 95%, 30 % and 99 %, 50% and 95%, 50 %
and 99 %, 75 % and 99 %, or 85 % and 99 %. The amount of LMW protein may be reduced by
about any of 5 %, 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, or 95 %. In some
embodiments, the reduction is determined by comparing the amount of fragmented protein (e.g.,
LMW protein) in the composition recovered from a purification step(s) to the amount of
fragmented protein (e.g., LMW protein) in the composition before the purification step(s).
Leached Protein A is Protein A detached or washed from a solid phase to which it is
bound. For example, leached Protein A can be leached from Protein A chromatography column.
The amount of Protein A may be measured, for example, by ELISA. In some embodiments of
any of the methods described herein, the amount of leached Protein A is reduced by greater than
about any of 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, or 90 %. The amount of leached
Protein A may be reduced by between about any of 10 % and 99 %, 30% and 95%, 30 % and 99
%, 50% and 95%, 50 % and 99 %, 75 % and 99 %, or 85 % and 99 %. In some embodiments,
the amount of leached Protein A is reduced by about any of 10 %, 20 %, 30 %, 40 %, 50 %, 60
%, 70 %, 80 %, 90 %, or 95 %. In some embodiments, the reduction is determined by comparing
the amount of leached Protein A in the composition recovered from a purification step(s) to the
amount of leached Protein A in the composition before the purification step(s).
Methods of measuring DNA such as host cell DNA are known in the art and described
in the examples section. In some embodiments of any of the methods described herein, the
amount of DNA is reduced by greater than about any of 10 %, 20 %, 30 %, 40 %, 50 %, 60 %,
70 %, 80 %, or 90 %. The amount of DNA may be reduced by between about any of 10 % and
99 %, 30% and 95%, 30 % and 99 %, 50% and 95%, 50 % and 99 %, 75 % and 99 %, or 85 %
and 99 %. The amount of DNA may be reduced by about any of 10 %, 20 %, 30 %, 40 %, 50 %,
60 %, 70 %, 80 %, 90 %, 95 %, or 99 %. In some embodiments, the reduction is determined by
comparing the amount of DNA in the composition recovered from a purification step(s) to the
amount of DNA in the composition before the purification step(s).
Cell culture media component refers to a component present in a cell culture media. A
cell culture media may be a cell culture media at the time of harvesting cells. In some
embodiments, the cell culture media component is gentamicin. The amount of gentamicin may
be measured by ELISA. In some embodiments of any of the methods described herein, the
amount of cell culture media component is reduced by greater than about any of 10 %, 20 %, 30
%, 40 %, 50 %, 60 %, 70 %, 80 %, or 90 %. The amount of cell culture media component may
be reduced by between about any of 10 % and 99 %, 30% and 95%, 30 % and 99 %, 50% and
95%, 50 % and 99 %, 75 % and 99 %, or 85 % and 99 %. In some embodiments, the amount of
cell culture media component is reduced by about any of 10 %, 20 %, 30 %, 40 %, 50 %, 60 %,
70 %, 80 %, 90 %, 95 %, or 98 %. In some embodiments, the reduction is determined by
comparing the amount of cell culture media component in the composition recovered from a
purification step(s) to the amount of cell culture media component in the composition before the
purification step(s).
In some embodiments of any of the methods described herein, the methods may further
comprise one or more purification steps either prior to, or after, any of the OEC described
herein. Other purification procedures include, for example, ion exchange chromatography such
as anion exchange chromatography and cation exchange chromatography, affinity
chromatography such as protein A chromatography and protein G chromatography, mixed mode
chromatography, hydroxylapatite chromatography; gel filtration chromatography; affinity
chromatography; gel electrophoresis; dialysis; ethanol precipitation; reverse phase HPLC;
chromatography on silica; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; and
metal chelating columns to bind epitope-tagged forms of the polypeptide.
In some embodiments of any of the methods described herein, the methods further
comprise recovering the purified polypeptide. In some embodiments, the purified polypeptide is
recovered from any of the purification steps described herein. The chromatography step may be
cation exchange chromatography, mixed mode chromatography, or Protein A chromatography.
In some embodiments, the OEC chromatography is a mixed mode chromatography and the
further chromatography is an anion exchange chromatography. In some embodiments, the OEC
chromatography is a mixed mode chromatography and the further chromatography is a cation
exchange chromatography. In some embodiments, the OEC chromatography is a mixed mode
chromatography and the further chromatography is a HIC chromatography. In some
embodiments, the OEC chromatography is an anion exchange chromatography and the further
chromatography is a cation exchange chromatography. In some embodiments, the OEC
chromatography is an anion exchange chromatography and the further chromatography is a
mixed mode chromatography. In some embodiments, the OEC chromatography is an anion
exchange chromatography and the further chromatography is a HIC chromatography. In some
embodiments, the OEC chromatography is a cation exchange chromatography and the further
chromatography is an anion exchange chromatography. In some embodiments, the OEC
chromatography is a cation exchange chromatography and the further chromatography is a
mixed mode chromatography. In some embodiments, the OEC chromatography is a cation
exchange chromatography and the further chromatography is a HIC chromatography. In some
embodiments, the OEC chromatography is a HIC chromatography and the further
chromatography is a mixed mode chromatography. In some embodiments, the OEC
chromatography is a HIC chromatography and the further chromatography is an anion exchange
chromatography. In some embodiments, the OEC chromatography is a HIC chromatography and
the further chromatography is a cation exchange chromatography.
In some embodiments, the polypeptide is further purified following OEC by viral
filtration. Viral filtration is the removal of viral contaminants in a polypeptide purification
feedstream. Examples of viral filtration include ultrafiltration and microfiltration. In some
embodiments the polypeptide is purified using a parvovirus filter.
In some embodiments, the polypeptide is concentrated after chromatography by OEC
mode. Examples of concentration methods are known in the art and include but are not limited
to ultrafiltration and diafiltration.
In some embodiments of any of the methods described herein, the methods further
comprise combining the purified polypeptide of the methods of purification with a
pharmaceutically acceptable carrier.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto Adhere resin at a load density of 150
– 200 g antibody per liter of Capto Adhere resin in a loading buffer with a pH of about 6.5 and a
conductivity of about 5.3 mS/cm to about 5.6 mS/cm; b) eluting the antibody from the resin with
an elution buffer comprising 100 mM 2-(N-morpholino)ethanesulfonic acid (MES) with a pH of
about 6.5 and a conductivity of about 1 mS/cm; and collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto Adhere resin in a 1.6 – 10.8 L
column at a load density of 70-180 g antibody per liter of Capto Adhere resin in a loading buffer
with a pH of about 6.5 and a conductivity of about 5.3 mS/cm to about 5.6 mS/cm; b) eluting the
antibody from the resin with an elution buffer comprising 100 mM MES with a pH of about 6.5
and a conductivity of about 1 mS/cm; and collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto Adhere resin at a load density of
about 200 g antibody per liter of Capto Adhere resin in a loading buffer with a pH of about 8.6
and a conductivity of about less than 6 mS/cm; b) eluting the antibody from the resin with an
elution buffer of 20 mM MES with a pH of about 6.5 and a conductivity of about 1 mS/cm; and
collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto Adhere resin at a load density of
about 200 g antibody per liter of Capto Adhere resin in a loading buffer with a pH of about 6.1
and a conductivity of about less than 6 mS/cm; b) eluting the antibody from the resin with an
elution buffer of 20 mM MES with a pH of about 6.0 and a conductivity of about 0.65 mS/cm;
and collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto Adhere resin at a load density of
about 200 g antibody per liter of Capto Adhere resin in a loading buffer with a pH of about 5.5
and a conductivity of about less than 6 mS/cm; b) eluting the antibody from the resin with an
elution buffer of 20 mM MES with a pH of about 4.9 and a conductivity of about 1.1 mS/cm;
and collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto Adhere resin at a load density of
about 200 g antibody per liter of Capto Adhere resin in a loading buffer with a pH of about 6.5
and a conductivity of about less than 6 mS/cm; b) eluting the antibody from the resin with an
elution buffer of 20 mM MES with a pH of about 6.5 and a conductivity of about 1 mS/cm; and
collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a QMA resin at a load density of about 103 g
antibody per liter of QMA resin in a loading buffer with a pH of about 6.5 and a conductivity of
about less than 5.5 mS/cm; b) eluting the antibody from the resin with an elution buffer of 20
mM MES with a pH of about 6.5 and a conductivity of about 1 mS/cm; and collecting a pool
comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Poros XS resin at a load density of about
200 g antibody per liter of Poros XS resin in a loading buffer with a pH of about 5.5 and a
conductivity of about less than 6 mS/cm; b) eluting the antibody from the resin with a 50-350
mM acetate elution buffer with a pH of about 5.5; and collecting a pool comprising the antibody.
In some embodiments, described are methods to purify an antibody comprising a)
loading a composition comprising the antibody on a Capto MMC resin at a load density of about
147 g antibody per liter of Capto MMC resin in a loading buffer with a pH of about 7.0 and a
conductivity of about less than 6 mS/cm; b) eluting the antibody from the resin with an elution
buffer of 20 mM MES with a pH of about 6.5 and a conductivity of about 1 mS/cm; and
collecting a pool comprising the antibody.
III. Polypeptides
Polypeptides are provided for use in any of the methods of purifying polypeptides and
formulations comprising the polypeptides purified by the methods described herein.
In some embodiments, described are methods to purify a polypeptide by using
overload and elute chromatography. In some embodiments, the polypeptide is a therapeutic
polypeptide. In some embodiments, the polypeptide is an antagonist. In some embodiments, the
polypeptide is an agonist. In some embodiments, the polypeptide is an antibody. In some
embodiments, the polypeptide is epitope tagged. In some embodiments, the polypeptide retains
a biological and/or immunological activity. In some embodiments, the polypeptide is an
antagonist. In some embodiments, the polypeptide initiates complement dependent cytotoxicity.
In some embodiments the polypeptide is an antibody or immunoadhesin. In further
embodiments of the above embodiments, the polypeptide is purified by OEC using a mixed
mode chromatography media. In further embodiments of the above embodiments, the
polypeptide is purified by OEC using an anion exchange chromatography media. In further
embodiments of the above embodiments, the polypeptide is purified by OEC using a cation
exchange chromatography media. In further embodiments of the above embodiments, the
polypeptide is purified by OEC using a HIC chromatography media. In further embodiments of
the above embodiments, the polypeptide is purified by OEC using a HAP chromatography
media. In further embodiments of the above embodiments, the polypeptide is purified by OEC
using an affinity chromatography media. In further embodiments of the above embodiments, the
polypeptide is purified by OEC using a chromatography media that is not, or does not include, a
cation exchange chromatography.
In some embodiments, the polypeptide has a molecular weight of greater than about
any of 5,000 Daltons, 10,000 Daltons, 15,000 Daltons, 25,000 Daltons, 50,000 Daltons, 75,000
Daltons, 100,000 Dalton, 125,000 Daltons, or 150,000 Daltons. The polypeptide may have a
molecular weight between about any of 50,000 Daltons to 200,000 Daltons or 100,000 Daltons
to 200,000 Daltons. Alternatively, the polypeptide for use herein may have a molecular weight
of about 120,000 Daltons or about 25,000 Daltons.
pI is the isoelectric point and is the pH at which a particular molecule or surface carries
no net electrical charge. In some embodiments of any of the methods described herein, the pI of
the polypeptide may be between about any of 6 to 10, 7 to 9, or 8 to 9. In some embodiments,
the polypeptide has a pI of about any of 6, 7, 7.5, 8, 8.5, 9, 9.5, or 10.
The polypeptides to be purified using the methods described herein is generally
produced using recombinant techniques. Methods for producing recombinant proteins are
described, e.g., in U.S. Pat Nos. 5,534,615 and 4,816,567, specifically incorporated herein by
reference. In some embodiments, the protein of interest is produced in a CHO cell (see, e.g. WO
94/11026). When using recombinant techniques, the polypeptides can be produced
intracellularly, in the periplasmic space, or directly secreted into the medium.
The polypeptides may be recovered from culture medium or from host cell lysates.
Cells employed in expression of the polypeptides can be disrupted by various physical or
chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing
agents. If the polypeptide is produced intracellularly, as a first step, the particulate debris, either
host cells or lysed fragments, are removed, for example, by centrifugation or ultrafiltration.
Carter et al., Bio/Technology 10: 163-167 (1992) describe a procedure for isolating polypeptides
which are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the
presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over
about 30 min. Cell debris can be removed by centrifugation. Where the polypeptide is secreted
into the medium, supernatants from such expression systems are generally first concentrated
using a commercially available polypeptide concentration filter, for example, an Amicon or
Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any
of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the
growth of adventitious contaminants.
Examples of polypeptides that may be purified by the methods described include but
are not limited to immunoglobulins, immunoadhesins, antibodies, enzymes, hormones, fusion
proteins, Fc-containing proteins, immunoconjugates, cytokines and interleukins. Examples of
polypeptide include, but are not limited to, mammalian proteins, such as, e.g., renin; a hormone;
a growth hormone, including human growth hormone and bovine growth hormone; growth
hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins;
alphaantitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone;
calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue
factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic
factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type
plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis
factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell
expressed and secreted); human macrophage inflammatory protein (MIPalpha); a serum
albumin such as human serum albumin; Muellerian-inhibiting substance; relaxin A-chain;
relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; an enzyme; a microbial
protein, such as beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associated antigen
(CTLA), such as CTLA-4; inhibin; activin; vascular endothelial growth factor (VEGF);
receptors for hormones or growth factors; protein A or D; rheumatoid factors; a neurotrophic
factor such as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3,
NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF-b; platelet-derived growth factor
(PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF);
transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF- β1, TGF-
β2, TGF- β3, TGF- β4, or TGF- β5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-
3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins (IGFBPs); a cytokine; CD
proteins such as CD3, CD4, CD8, CD19 and CD20; erythropoietin; osteoinductive factors;
immunotoxins; a fusion polypeptide, i.e. a polypeptide comprised on two or more heterologous
polypeptides or fragments thereof and encoded by a recombinant nucleic acid; an Fc-containing
polypeptide, for example, a fusion protein comprising an immunoglobulin Fc region, or
fragment thereof, fused to a second polypeptide; an immunoconjugate; a bone morphogenetic
protein (BMP); an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating
factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10;
superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor;
viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing
receptors; addressins; regulatory proteins; integrins such as CD11a, CD11b, CD11c, CD18, an
ICAM, VLA-4 and VCAM; a tumor associated antigen such as CA125 (ovarian cancer antigen)
or HER2, HER3 or HER4 receptor; immunoadhesins; and fragments and/or variants of any of
the above-listed proteins as well as antibodies, including antibody fragments, binding to a
protein, including, for example, any of the above-listed proteins.
(A) Antibodies
In some embodiments of any of the methods described herein, the polypeptide for use
in any of the methods of purifying polypeptides and formulations comprising the polypeptides
purified by the methods described herein is an antibody.
Molecular targets for antibodies include CD proteins and their ligands, such as, but not
limited to: (i) CD3, CD4, CD8, CD19, CD11a, CD20, CD22, CD34, CD40, CD79 α (CD79a),
and CD79 β (CD79b); (ii) members of the ErbB receptor family such as the EGF receptor,
HER2, HER3 or HER4 receptor; (iii) cell adhesion molecules such as LFA-1, Mac1, p150,95,
VLA-4, ICAM-1, VCAM and αv/ β3 integrin, including either alpha or beta subunits thereof
(e.g., anti-CD11a, anti-CD18 or anti-CD11b antibodies); (iv) growth factors such as VEGF; IgE;
blood group antigens; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein
C, BR3, c-met, tissue factor, β7 etc; and (v) cell surface and transmembrane tumor-associated
antigens (TAA), such as those described in U.S. Patent No. 7,521,541.
Other exemplary antibodies include those selected from, and without limitation, anti-
estrogen receptor antibody, anti-progesterone receptor antibody, anti-p53 antibody, anti-HER-
2/neu antibody, anti-EGFR antibody, anti-cathepsin D antibody, anti-Bcl-2 antibody, anti-E-
cadherin antibody, anti-CA125 antibody, anti-CA15-3 antibody, anti-CA19-9 antibody, anti-c-
erbB-2 antibody, anti-P-glycoprotein antibody, anti-CEA antibody, anti-retinoblastoma protein
antibody, anti-ras oncoprotein antibody, anti-Lewis X antibody, anti-Ki-67 antibody, anti-PCNA
antibody, anti-CD3 antibody, anti-CD4 antibody, anti-CD5 antibody, anti-CD7 antibody, anti-
CD8 antibody, anti-CD9/p24 antibody, anti-CD10 antibody, anti-CD11a antibody, anti-CD11c
antibody, anti-CD13 antibody, anti-CD14 antibody, anti-CD15 antibody, anti-CD19 antibody,
anti-CD20 antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD30 antibody, anti-CD31
antibody, anti-CD33 antibody, anti-CD34 antibody, anti-CD35 antibody, anti-CD38 antibody,
anti-CD41 antibody, anti-LCA/CD45 antibody, anti-CD45RO antibody, anti-CD45RA antibody,
anti-CD39 antibody, anti-CD100 antibody, anti-CD95/Fas antibody, anti-CD99 antibody, anti-
CD106 antibody, anti-ubiquitin antibody, anti-CD71 antibody, anti-c-myc antibody, anti-
cytokeratins antibody, anti-vimentins antibody, anti-HPV proteins antibody, anti-kappa light
chains antibody, anti-lambda light chains antibody, anti-melanosomes antibody, anti-prostate
specific antigen antibody, anti-S-100 antibody, anti-tau antigen antibody, anti-fibrin antibody,
anti-keratins antibody and anti-Tn-antigen antibody.
(i) Polyclonal antibodies
In some embodiments, the antibodies are polyclonal antibodies. Polyclonal antibodies
are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections
of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a
polypeptide that is immunogenic in the species to be immunized, e.g., keyhole limpet
hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a
bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester
(conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues),
glutaraldehyde, succinic anhydride, SOCl , or R N=C=NR, where R and R are different alkyl
groups.
Animals are immunized against the antigen, immunogenic conjugates, or derivatives
by combining, e.g., 100 μg or 5 μg of the polypeptide or conjugate (for rabbits or mice,
respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution
intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the
original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection
at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for
antibody titer. Animals are boosted until the titer plateaus. In some embodiments, the animal is
boosted with the conjugate of the same antigen, but conjugated to a different polypeptide and/or
through a different cross-linking reagent. Conjugates also can be made in recombinant cell
culture as polypeptide fusions. Also, aggregating agents such as alum are suitably used to
enhance the immune response.
(ii) Monoclonal antibodies
In some embodiments, the antibodies are monoclonal antibodies. Monoclonal
antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the
individual antibodies comprising the population are identical and/or bind the same epitope
except for possible variants that arise during production of the monoclonal antibody, such
variants generally being present in minor amounts. Thus, the modifier “monoclonal” indicates
the character of the antibody as not being a mixture of discrete or polyclonal antibodies.
For example, the monoclonal antibodies may be made using the hybridoma method
first described by Kohler et al., Nature 256:495 (1975), or may be made by recombinant DNA
methods (U.S. Patent No. 4,816,567).
In the hybridoma method, a mouse or other appropriate host animal, such as a hamster,
is immunized as herein described to elicit lymphocytes that produce or are capable of producing
antibodies that will specifically bind to the polypeptide used for immunization. Alternatively,
lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using
a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding,
Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)).
The hybridoma cells thus prepared are seeded and grown in a suitable culture medium
that preferably contains one or more substances that inhibit the growth or survival of the
unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme
hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for
the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT
medium), which substances prevent the growth of HGPRT-deficient cells.
In some embodiments, the myeloma cells are those that fuse efficiently, support stable
high-level production of antibody by the selected antibody-producing cells, and are sensitive to a
medium such as HAT medium. Among these, in some embodiments, the myeloma cell lines are
murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors
available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2
or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville,
Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been
described for the production of human monoclonal antibodies (Kozbor, J. Immunol. 133:3001
(1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications pp. 51-63
(Marcel Dekker, Inc., New York, 1987)).
Culture medium in which hybridoma cells are growing is assayed for production of
monoclonal antibodies directed against the antigen. In some embodiments, the binding
specificity of monoclonal antibodies produced by hybridoma cells is determined by
immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or
enzyme-linked immunoabsorbent assay (ELISA).
The binding affinity of the monoclonal antibody can, for example, be determined by
the Scatchard analysis of Munson et al., Anal. Biochem. 107:220 (1980).
After hybridoma cells are identified that produce antibodies of the desired specificity,
affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown
by standard methods (Goding, Monoclonal Antibodies: Principles and Practice pp. 59-103
(Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM
or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors
in an animal.
The monoclonal antibodies secreted by the subclones are suitably separated from the
culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures
such as, for example, polypeptide A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography.
DNA encoding the monoclonal antibodies is readily isolated and sequenced using
conventional procedures (e.g., by using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of murine antibodies). In some
embodiments, the hybridoma cells serve as a source of such DNA. Once isolated, the DNA may
be placed into expression vectors, which are then transfected into host cells such as E. coli cells,
simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise
produce immunoglobulin polypeptide, to obtain the synthesis of monoclonal antibodies in the
recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding
the antibody include Skerra et al., Curr. Opinion in Immunol. 5:256-262 (1993) and Plückthun,
Immunol. Revs., 130:151-188 (1992).
In a further embodiment, antibodies or antibody fragments can be isolated from
antibody phage libraries generated using the techniques described in McCafferty et al., Nature
348:552-554 (1990). Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol.
222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using
phage libraries. Subsequent publications describe the production of high affinity (nM range)
human antibodies by chain shuffling (Marks et al., Bio/Technology 10:779-783 (1992)), as well
as combinatorial infection and in vivo recombination as a strategy for constructing very large
phage libraries (Waterhouse et al., Nuc. Acids. Res. 21:2265-2266 (1993)). Thus, these
techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for
isolation of monoclonal antibodies.
The DNA also may be modified, for example, by substituting the coding sequence for
human heavy- and light chain constant domains in place of the homologous murine sequences
(U.S. Patent No. 4,816,567; Morrison et al., Proc. Natl Acad. Sci. USA 81:6851 (1984)), or by
covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for
a non-immunoglobulin polypeptide.
Typically such non-immunoglobulin polypeptides are substituted for the constant
domains of an antibody, or they are substituted for the variable domains of one antigen-
combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-
combining site having specificity for an antigen and another antigen-combining site having
specificity for a different antigen.
In some embodiments of any of the methods described herein, the antibody is IgA,
IgD, IgE, IgG, or IgM. In some embodiments, the antibody is an IgG monoclonal antibody.
(iii) Humanized antibodies
In some embodiments, the antibody is a humanized antibody. Methods for humanizing
non-human antibodies have been described in the art. In some embodiments, a humanized
antibody has one or more amino acid residues introduced into it from a source that is non-
human. These non-human amino acid residues are often referred to as “import” residues, which
are typically taken from an “import” variable domain. Humanization can be essentially
performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525
(1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536
(1988)), by substituting hypervariable region sequences for the corresponding sequences of a
human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent
No. 4,816,567) wherein substantially less than an intact human variable domain has been
substituted by the corresponding sequence from a non-human species. In practice, humanized
antibodies are typically human antibodies in which some hypervariable region residues and
possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
The choice of human variable domains, both light and heavy, to be used in making the
humanized antibodies is very important to reduce antigenicity. According to the so-called "best-
fit" method, the sequence of the variable domain of a rodent antibody is screened against the
entire library of known human variable-domain sequences. The human sequence that is closest
to that of the rodent is then accepted as the human framework region (FR) for the humanized
antibody (Sims et al., J. Immunol. 151:2296 (1993); Chothia et al., J. Mol. Biol. 196:901
(1987)). Another method uses a particular framework region derived from the consensus
sequence of all human antibodies of a particular subgroup of light or heavy chain variable
regions. The same framework may be used for several different humanized antibodies (Carter et
al., Proc. Natl. Acad. Sci. USA 89:4285 (1992); Presta et al., J. Immunol. 151:2623 (1993)).
It is further important that antibodies be humanized with retention of high affinity for
the antigen and other favorable biological properties. To achieve this goal, in some embodiments
of the methods, humanized antibodies are prepared by a process of analysis of the parental
sequences and various conceptual humanized products using three-dimensional models of the
parental and humanized sequences. Three-dimensional immunoglobulin models are commonly
available and are familiar to those skilled in the art. Computer programs are available that
illustrate and display probable three-dimensional conformational structures of selected candidate
immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the
residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of
residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this
way, FR residues can be selected and combined from the recipient and import sequences so that
the desired antibody characteristic, such as increased affinity for the target antigen(s), is
achieved. In general, the hypervariable region residues are directly and most substantially
involved in influencing antigen binding.
(v) Human antibodies
In some embodiments, the antibody is a human antibody. As an alternative to
humanization, human antibodies can be generated. For example, it is now possible to produce
transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full
repertoire of human antibodies in the absence of endogenous immunoglobulin production. For
example, it has been described that the homozygous deletion of the antibody heavy chain joining
region (J ) gene in chimeric and germ-line mutant mice results in complete inhibition of
endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array
in such germ-line mutant mice will result in the production of human antibodies upon antigen
challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA 90:2551 (1993); Jakobovits et
al., Nature 362:255-258 (1993); Bruggermann et al., Year in Immuno. 7:33 (1993); and US
Patent Nos. 5,591,669; 5,589,369; and 5,545,807.
Alternatively, phage display technology (McCafferty et al., Nature 348:552-553
(1990)) can be used to produce human antibodies and antibody fragments in vitro, from
immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to
this technique, antibody V domain genes are cloned in-frame into either a major or minor coat
polypeptide gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional
antibody fragments on the surface of the phage particle. Because the filamentous particle
contains a single-stranded DNA copy of the phage genome, selections based on the functional
properties of the antibody also result in selection of the gene encoding the antibody exhibiting
those properties. Thus, the phage mimics some of the properties of the B cell. Phage display can
be performed in a variety of formats; for their review see, e.g., Johnson, Kevin S. and Chiswell,
David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources of V-gene
segments can be used for phage display. Clackson et al., Nature 352:624-628 (1991) isolated a
diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes
derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human
donors can be constructed and antibodies to a diverse array of antigens (including self-antigens)
can be isolated essentially following the techniques described by Marks et al., J. Mol. Biol.
222:581-597 (1991), or Griffith et al., EMBO J. 12:725-734 (1993). See also, US Patent Nos.
,565,332 and 5,573,905.
Human antibodies may also be generated by in vitro activated B cells (see US Patents
,567,610 and 5,229,275).
(v) Antibody fragments
In some embodiments, the antibody is an antibody fragment. Various techniques have
been developed for the production of antibody fragments. Traditionally, these fragments were
derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of
Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81
(1985)). However, these fragments can now be produced directly by recombinant host cells. For
example, the antibody fragments can be isolated from the antibody phage libraries discussed
above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically
coupled to form F(ab') fragments (Carter et al., Bio/Technology 10:163-167 (1992)). According
to another approach, F(ab') fragments can be isolated directly from recombinant host cell
culture. Other techniques for the production of antibody fragments will be apparent to the skilled
practitioner. In other embodiments, the antibody of choice is a single chain Fv fragment (scFv).
See WO 93/16185; US Patent No. 5,571,894; and US Patent No. 5,587,458. The antibody
fragment may also be a “linear antibody,” e.g., as described in US Patent 5,641,870 for example.
Such linear antibody fragments may be monospecific or bispecific.
In some embodiments, fragments of the antibodies described herein are provided. In
some embodiments, the antibody fragment is an antigen binding fragment. In some
embodiments, the antigen binding fragment is selected from the group consisting of a Fab
fragment, a Fab’ fragment, a F(ab’) fragment, a scFv, a Fv, and a diabody.
(vi) Bispecific antibodies
In some embodiments, the antibody is a bispecific antibody. Bispecific antibodies are
antibodies that have binding specificities for at least two different epitopes. Exemplary
bispecific antibodies may bind to two different epitopes. Alternatively, a bispecific antibody
binding arm may be combined with an arm that binds to a triggering molecule on a leukocyte
such as a T-cell receptor molecule (e.g. CD2 or CD3), or Fc receptors for IgG (Fc γR), such as
Fc γRI (CD64), Fc γRII (CD32) and Fc γRIII (CD16) so as to focus cellular defense mechanisms
to the cell. Bispecific antibodies can be prepared as full length antibodies or antibody fragments
(e.g. F(ab') bispecific antibodies).
Methods for making bispecific antibodies are known in the art. Traditional production
of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy
chain-light chain pairs, where the two chains have different specificities (Millstein et al., Nature
305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light
chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody
molecules, of which only one has the correct bispecific structure. Purification of the correct
molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and
the product yields are low. Similar procedures are disclosed in WO 93/08829, and in Traunecker
et al., EMBO J., 10:3655-3659 (1991).
According to a different approach, antibody variable domains with the desired binding
specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain
sequences. In some embodiments, the fusion is with an immunoglobulin heavy chain constant
domain, comprising at least part of the hinge, CH2, and CH3 regions. In some embodiments, the
first heavy chain constant region (CH1) containing the site necessary for light chain binding,
present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions
and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors,
and are co-transfected into a suitable host organism. This provides for great flexibility in
adjusting the mutual proportions of the three polypeptide fragments in embodiments when
unequal ratios of the three polypeptide chains used in the construction provide the optimum
yields. It is, however, possible to insert the coding sequences for two or all three polypeptide
chains in one expression vector when the expression of at least two polypeptide chains in equal
ratios results in high yields or when the ratios are of no particular significance.
In some embodiments of this approach, the bispecific antibodies are composed of a
hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid
immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the
other arm. It was found that this asymmetric structure facilitates the separation of the desired
bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an
immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way
of separation. This approach is disclosed in WO 94/04690. For further details of generating
bispecific antibodies see, for example, Suresh et al., Methods in Enzymology 121:210 (1986).
According to another approach described in US Patent No. 5,731,168, the interface
between a pair of antibody molecules can be engineered to maximize the percentage of
heterodimers that are recovered from recombinant cell culture. In some embodiments, the
interface comprises at least a part of the C 3 domain of an antibody constant domain. In this
method, one or more small amino acid side chains from the interface of the first antibody
molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory
"cavities" of identical or similar size to the large side chain(s) are created on the interface of the
second antibody molecule by replacing large amino acid side chains with smaller ones (e.g.
alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer
over other unwanted end-products such as homodimers.
Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For
example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to
biotin. Such antibodies have, for example, been proposed to target immune system cells to
unwanted cells (US Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360,
WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient
cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed
in US Patent No. 4,676,980, along with a number of cross-linking techniques.
Techniques for generating bispecific antibodies from antibody fragments have also
been described in the literature. For example, bispecific antibodies can be prepared using
chemical linkage. Brennan et al., Science 229: 81 (1985) describe a procedure wherein intact
antibodies are proteolytically cleaved to generate F(ab') fragments. These fragments are
reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal
dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then
converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then
reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an
equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The
bispecific antibodies produced can be used as agents for the selective immobilization of
enzymes.
Various techniques for making and isolating bispecific antibody fragments directly
from recombinant cell culture have also been described. For example, bispecific antibodies have
been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The
leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two
different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region
to form monomers and then re-oxidized to form the antibody heterodimers. This method can
also be utilized for the production of antibody homodimers. The "diabody" technology described
by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative
mechanism for making bispecific antibody fragments. The fragments comprise a heavy chain
variable domain (V ) connected to a light chain variable domain (V ) by a linker that is too
short to allow pairing between the two domains on the same chain. Accordingly, the V and V
domains of one fragment are forced to pair with the complementary V and V domains of
another fragment, thereby forming two antigen-binding sites. Another strategy for making
bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported.
See Gruber et al., J. Immunol. 152:5368 (1994).
Antibodies with more than two valencies are contemplated. For example, trispecific
antibodies can be prepared. Tutt et al., J. Immunol. 147: 60 (1991).
(vii) Multivalent Antibodies
In some embodiments, the antibodies are multivalent antibodies. A multivalent
antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell
expressing an antigen to which the antibodies bind. The antibodies provided herein can be
multivalent antibodies (which are other than of the IgM class) with three or more antigen
binding sites (e.g., tetravalent antibodies), which can be readily produced by recombinant
expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent
antibody can comprise a dimerization domain and three or more antigen binding sites. The
preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this
scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-
terminal to the Fc region. The preferred multivalent antibody herein comprises (or consists of)
three to about eight, but preferably four, antigen binding sites. The multivalent antibody
comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the
polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide
chain(s) may comprise VD1-(X1)n-VD2-(X2) n-Fc, wherein VD1 is a first variable domain,
VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, X1 and X2
represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s)
may comprise: VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fc
region chain. The multivalent antibody herein preferably further comprises at least two (and
preferably four) light chain variable domain polypeptides. The multivalent antibody herein may,
for instance, comprise from about two to about eight light chain variable domain polypeptides.
The light chain variable domain polypeptides contemplated here comprise a light chain variable
domain and, optionally, further comprise a CL domain.
In some embodiments, the antibody is a multispecific antibody. Example of
multispecific antibodies include, but are not limited to, an antibody comprising a heavy chain
variable domain (V ) and a light chain variable domain (V ), where the V V unit has
H L H L
polyepitopic specificity, antibodies having two or more V and V domains with each V V unit
L H H L
binding to a different epitope, antibodies having two or more single variable domains with each
single variable domain binding to a different epitope, full length antibodies, antibody fragments
such as Fab, Fv, dsFv, scFv, diabodies, bispecific diabodies, triabodies, tri-functional antibodies,
antibody fragments that have been linked covalently or non-covalently. In some embodiment
that antibody has polyepitopic specificity; for example, the ability to specifically bind to two or
more different epitopes on the same or different target(s). In some embodiments, the antibodies
are monospecific; for example, an antibody that binds only one epitope. According to one
embodiment the multispecific antibody is an IgG antibody that binds to each epitope with an
affinity of 5 mM to 0.001 pM, 3 mM to 0.001 pM, 1 mM to 0.001 pM, 0.5 mM to 0.001 pM, or
0.1 mM to 0.001 pM.
(viii) Other Antibody Modifications
It may be desirable to modify the antibody provided herein with respect to effector
function, e.g., so as to enhance antigen-dependent cell-mediated cyotoxicity (ADCC) and/or
complement dependent cytotoxicity (CDC) of the antibody. This may be achieved by
introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively
or additionally, cysteine residue(s) may be introduced in the Fc region, thereby allowing
interchain disulfide bond formation in this region. The homodimeric antibody thus generated
may have improved internalization capability and/or increased complement-mediated cell killing
and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med. 176:1191-
1195 (1992) and Shopes, B. J., Immunol. 148:2918-2922 (1992). Homodimeric antibodies with
enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as
described in Wolff et al., Cancer Research 53:2560-2565 (1993). Alternatively, an antibody can
be engineered which has dual Fc regions and may thereby have enhanced complement mediated
lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design 3:219-230 (1989).
For increasing serum half the serum half life of the antibody, amino acid alterations
can be made in the antibody as described in US 2006/0067930, which is hereby incorporated by
reference in its entirety.
(B) Polypeptide Variants and Modifications
Amino acid sequence modification(s) of the polypeptides, including antibodies,
described herein may be used in the methods of purifying polypeptides (e.g., antibodies)
described herein.
(i) Variant Polypeptides
“Polypeptide variant” means a polypeptide, preferably an active polypeptide, as
defined herein having at least about 80% amino acid sequence identity with a full-length native
sequence of the polypeptide, a polypeptide sequence lacking the signal peptide, an extracellular
domain of a polypeptide, with or without the signal peptide. Such polypeptide variants include,
for instance, polypeptides wherein one or more amino acid residues are added, or deleted, at the
N or C-terminus of the full-length native amino acid sequence. Ordinarily, a TAT polypeptide
variant will have at least about 80% amino acid sequence identity, alternatively at least about
any of 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity, to a full-length
native sequence polypeptide sequence, a polypeptide sequence lacking the signal peptide, an
extracellular domain of a polypeptide, with or without the signal peptide. Optionally, variant
polypeptides will have no more than one conservative amino acid substitution as compared to
the native polypeptide sequence, alternatively no more than about any of 2, 3, 4, 5, 6, 7, 8, 9, or
conservative amino acid substitution as compared to the native polypeptide sequence.
The variant polypeptide may be truncated at the N-terminus or C-terminus, or may lack
internal residues, for example, when compared with a full length native polypeptide. Certain
variant polypeptides may lack amino acid residues that are not essential for a desired biological
activity. These variant polypeptides with truncations, deletions, and insertions may be prepared
by any of a number of conventional techniques. Desired variant polypeptides may be chemically
synthesized. Another suitable technique involves isolating and amplifying a nucleic acid
fragment encoding a desired variant polypeptide, by polymerase chain reaction (PCR).
Oligonucleotides that define the desired termini of the nucleic acid fragment are employed at the
' and 3' primers in the PCR. Preferably, variant polypeptides share at least one biological and/or
immunological activity with the native polypeptide disclosed herein.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions
ranging in length from one residue to polypeptides containing a hundred or more residues, as
well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal
insertions include an antibody with an N-terminal methionyl residue or the antibody fused to a
cytotoxic polypeptide. Other insertional variants of the antibody molecule include the fusion to
the N- or C-terminus of the antibody to an enzyme or a polypeptide which increases the serum
half-life of the antibody.
For example, it may be desirable to improve the binding affinity and/or other
biological properties of the polypeptide. Amino acid sequence variants of the polypeptide are
prepared by introducing appropriate nucleotide changes into the antibody nucleic acid, or by
peptide synthesis. Such modifications include, for example, deletions from, and/or insertions
into and/or substitutions of, residues within the amino acid sequences of the polypeptide. Any
combination of deletion, insertion, and substitution is made to arrive at the final construct,
provided that the final construct possesses the desired characteristics. The amino acid changes
also may alter post-translational processes of the polypeptide (e.g., antibody), such as changing
the number or position of glycosylation sites.
Guidance in determining which amino acid residue may be inserted, substituted or
deleted without adversely affecting the desired activity may be found by comparing the
sequence of the polypeptide with that of homologous known polypeptide molecules and
minimizing the number of amino acid sequence changes made in regions of high homology.
A useful method for identification of certain residues or regions of the polypeptide
(e.g., antibody) that are preferred locations for mutagenesis is called "alanine scanning
mutagenesis" as described by Cunningham and Wells, Science 244:1081-1085 (1989). Here, a
residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His,
Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably
Alanine or Polyalanine) to affect the interaction of the amino acids with antigen. Those amino
acid locations demonstrating functional sensitivity to the substitutions then are refined by
introducing further or other variants at, or for, the sites of substitution. Thus, while the site for
introducing an amino acid sequence variation is predetermined, the nature of the mutation per se
need not be predetermined. For example, to analyze the performance of a mutation at a given
site, ala scanning or random mutagenesis is conducted at the target codon or region and the
expressed antibody variants are screened for the desired activity.
Another type of variant is an amino acid substitution variant. These variants have at
least one amino acid residue in the antibody molecule replaced by a different residue. The sites
of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR
alterations are also contemplated. Conservative substitutions are shown in the Table 1 below
under the heading of “preferred substitutions.” If such substitutions result in a change in
biological activity, then more substantial changes, denominated "exemplary substitutions" in the
Table 1, or as further described below in reference to amino acid classes, may be introduced and
the products screened.
Table 1.
Original Exemplary Preferred
Residue Substitutions Substitutions
Ala (A) Val; Leu; Ile Val
Arg (R) Lys; Gln; Asn Lys
Asn (N) Gln; His; Asp, Lys; Arg Gln
Asp (D) Glu; Asn Glu
Cys (C) Ser; Ala Ser
Gln (Q) Asn; Glu Asn
Glu (E) Asp; Gln Asp
Gly (G) Ala Ala
His (H) Asn; Gln; Lys; Arg Arg
Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Leu
Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile
Lys (K) Arg; Gln; Asn Arg
Met (M) Leu; Phe; Ile Leu
Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr
Pro (P) Ala Ala
Ser (S) Thr Thr
Thr (T) Val; Ser Ser
Trp (W) Tyr; Phe Tyr
Tyr (Y) Trp; Phe; Thr; Ser Phe
Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu
Substantial modifications in the biological properties of the polypeptide are
accomplished by selecting substitutions that differ significantly in their effect on maintaining (a)
the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet
or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c)
the bulk of the side chain. Amino acids may be grouped according to similarities in the
properties of their side chains (in A. L. Lehninger, Biochemistry second ed., pp. 73-75, Worth
Publishers, New York (1975)):
(1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M)
(2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q)
(3) acidic: Asp (D), Glu (E)
(4) basic: Lys (K), Arg (R), His(H)
Alternatively, naturally occurring residues may be divided into groups based on
common side-chain properties:
(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
Non-conservative substitutions will entail exchanging a member of one of these classes
for another class.
Any cysteine residue not involved in maintaining the proper conformation of the
antibody also may be substituted, generally with serine, to improve the oxidative stability of the
molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the
polypeptide to improve its stability (particularly where the antibody is an antibody fragment
such as an Fv fragment).
A particularly preferred type of substitutional variant involves substituting one or more
hypervariable region residues of a parent antibody (e.g., a humanized antibody). Generally, the
resulting variant(s) selected for further development will have improved biological properties
relative to the parent antibody from which they are generated. A convenient way for generating
such substitutional variants involves affinity maturation using phage display. Briefly, several
hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino
substitutions at each site. The antibody variants thus generated are displayed in a monovalent
fashion from filamentous phage particles as fusions to the gene III product of M13 packaged
within each particle. The phage-displayed variants are then screened for their biological activity
(e.g., binding affinity) as herein disclosed. In order to identify candidate hypervariable region
sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable
region residues contributing significantly to antigen binding. Alternatively, or additionally, it
may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify
contact points between the antibody and target. Such contact residues and neighboring residues
are candidates for substitution according to the techniques elaborated herein. Once such variants
are generated, the panel of variants is subjected to screening as described herein and antibodies
with superior properties in one or more relevant assays may be selected for further development.
Another type of amino acid variant of the polypeptide alters the original glycosylation
pattern of the antibody. The polypeptide may comprise non-amino acid moieties. For example,
the polypeptide may be glycosylated. Such glycosylation may occur naturally during expression
of the polypeptide in the host cell or host organism, or may be a deliberate modification arising
from human intervention. By altering is meant deleting one or more carbohydrate moieties
found in the polypeptide, and/or adding one or more glycosylation sites that are not present in
the polypeptide.
Glycosylation of polypeptide is typically either N-linked or O-linked. N-linked refers
to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The
tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino
acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate
moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in
a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the
attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino
acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may
also be used.
Addition of glycosylation sites to the polypeptide is conveniently accomplished by
altering the amino acid sequence such that it contains one or more of the above-described
tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the
addition of, or substitution by, one or more serine or threonine residues to the sequence of the
original antibody (for O-linked glycosylation sites).
Removal of carbohydrate moieties present on the polypeptide may be accomplished
chemically or enzymatically or by mutational substitution of codons encoding for amino acid
residues that serve as targets for glycosylation. Enzymatic cleavage of carbohydrate moieties on
polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases.
Other modifications include deamidation of glutaminyl and asparaginyl residues to the
corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α-amino
groups of lysine, arginine, and histidine side chains, acetylation of the N-terminal amine, and
amidation of any C-terminal carboxyl group.
(ii) Chimeric Polypeptides
The polypeptide described herein may be modified in a way to form chimeric
molecules comprising the polypeptide fused to another, heterologous polypeptide or amino acid
sequence. In some embodiments, a chimeric molecule comprises a fusion of the polypeptide
with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively
bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of the polypeptide.
The presence of such epitope-tagged forms of the polypeptide can be detected using an antibody
against the tag polypeptide. Also, provision of the epitope tag enables the polypeptide to be
readily purified by affinity purification using an anti-tag antibody or another type of affinity
matrix that binds to the epitope tag.
In an alternative embodiment, the chimeric molecule may comprise a fusion of the
polypeptide with an immunoglobulin or a particular region of an immunoglobulin. A bivalent
form of the chimeric molecule is referred to as an “immunoadhesin.”
As used herein, the term “immunoadhesin” designates antibody-like molecules which
combine the binding specificity of a heterologous polypeptide with the effector functions of
immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an
amino acid sequence with the desired binding specificity which is other than the antigen
recognition and binding site of an antibody (i.e., is “heterologous”), and an immunoglobulin
constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a
contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from
any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and
IgA-2), IgE, IgD or IgM.
The Ig fusions preferably include the substitution of a soluble (transmembrane domain
deleted or inactivated) form of a polypeptide in place of at least one variable region within an Ig
molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the
hinge, CH and CH , or the hinge, CH , CH and CH regions of an IgG1 molecule.
2 3 1 2 3
(iii) Polypeptide Conjugates
The polypeptide for use in polypeptide formulations may be conjugated to a cytotoxic
agent such as a chemotherapeutic agent, a growth inhibitory agent, a toxin (e.g., an
enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or
a radioactive isotope (i.e., a radioconjugate).
Chemotherapeutic agents useful in the generation of such conjugates can be used. In
addition, enzymatically active toxins and fragments thereof that can be used include diphtheria
A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas
aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii
proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica
charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin,
restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are
212 131 131
available for the production of radioconjugated polypeptides. Examples include Bi, I, In,
90 186
Y, and Re. Conjugates of the polypeptide and cytotoxic agent are made using a variety of
bifunctional protein-coupling agents such as N-succinimidyl(2-pyridyldithiol) propionate
(SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl
adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as
glutareldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis-
diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such
as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-
dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al.,
Science 238: 1098 (1987). Carbonlabeled 1-isothiocyanatobenzylmethyldiethylene
triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the polypeptide.
Conjugates of a polypeptide and one or more small molecule toxins, such as a
calicheamicin, maytansinoids, a trichothene, and CC1065, and the derivatives of these toxins
that have toxin activity, are also contemplated herein.
Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization.
Maytansine was first isolated from the east African shrub Maytenus serrata. Subsequently, it
was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3
maytansinol esters. Synthetic maytansinol and derivatives and analogues thereof are also
contemplated. There are many linking groups known in the art for making polypeptide-
maytansinoid conjugates, including, for example, those disclosed in U.S. Pat. No. 5,208,020.
The linking groups include disufide groups, thioether groups, acid labile groups, photolabile
groups, peptidase labile groups, or esterase labile groups, as disclosed in the above-identified
patents, disulfide and thioether groups being preferred.
The linker may be attached to the maytansinoid molecule at various positions,
depending on the type of the link. For example, an ester linkage may be formed by reaction with
a hydroxyl group using conventional coupling techniques. The reaction may occur at the C-3
position having a hydroxyl group, the C-14 position modified with hyrdoxymethyl, the C-15
position modified with a hydroxyl group, and the C-20 position having a hydroxyl group. In a
preferred embodiment, the linkage is formed at the C-3 position of maytansinol or a maytansinol
analogue.
Another conjugate of interest comprises a polypeptide conjugated to one or more
calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing
double-stranded DNA breaks at sub-picomolar concentrations. For the preparation of conjugates
of the calicheamicin family, see, e.g., U.S. Pat. No. 5,712,374. Structural analogues of
I I I I
calicheamicin which may be used include, but are not limited to, γ , α , α , N-acetyl- γ , PSAG
1 2 3 1
and θ . Another anti-tumor drug that the antibody can be conjugated is QFA which is an
antifolate. Both calicheamicin and QFA have intracellular sites of action and do not readily cross
the plasma membrane. Therefore, cellular uptake of these agents through polypeptide (e.g.,
antibody) mediated internalization greatly enhances their cytotoxic effects.
Other antitumor agents that can be conjugated to the polypeptides described herein
include BCNU, streptozoicin, vincristine and 5-fluorouracil, the family of agents known
collectively LL-E33288 complex, as well as esperamicins.
In some embodiments, the polypeptide may be a conjugate between a polypeptide and
a compound with nucleolytic activity (e.g., a ribonuclease or a DNA endonuclease such as a
deoxyribonuclease; DNase).
In yet another embodiment, the polypeptide (e.g., antibody) may be conjugated to a
“receptor” (such streptavidin) for utilization in tumor pre-targeting wherein the polypeptide
receptor conjugate is administered to the patient, followed by removal of unbound conjugate
from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin)
which is conjugated to a cytotoxic agent (e.g., a radionucleotide).
In some embodiments, the polypeptide may be conjugated to a prodrug-activating
enzyme which converts a prodrug (e.g., a peptidyl chemotherapeutic agent) to an active anti-
cancer drug. The enzyme component of the immunoconjugate includes any enzyme capable of
acting on a prodrug in such a way so as to covert it into its more active, cytotoxic form.
Enzymes that are useful include, but are not limited to, alkaline phosphatase useful for
converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting
sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic
-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease,
thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are
useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases,
useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving
enzymes such as β-galactosidase and neuraminidase useful for converting glycosylated prodrugs
into free drugs; β-lactamase useful for converting drugs derivatized with β-lactams into free
drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for
converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl
groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also
known in the art as "abzymes", can be used to convert the prodrugs into free active drugs.
(iv) Other
Another type of covalent modification of the polypeptide comprises linking the
polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol,
polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and
polypropylene glycol. The polypeptide also may be entrapped in microcapsules prepared, for
example, by coacervation techniques or by interfacial polymerization (for example,
hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules,
respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres,
microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are
disclosed in Remington's Pharmaceutical Sciences, 18th edition, Gennaro, A.R., Ed., (1990).
IV. Obtaining Polypeptides for Use in the Formulations and Methods
The polypeptides used in the methods of purification described herein may be obtained
using methods well-known in the art, including the recombination methods. The following
sections provide guidance regarding these methods.
(A) Polynucleotides
“Polynucleotide,” or “nucleic acid,” as used interchangeably herein, refer to polymers
of nucleotides of any length, and include DNA and RNA.
Polynucleotides encoding polypeptides may be obtained from any source including,
but not limited to, a cDNA library prepared from tissue believed to possess the polypeptide
mRNA and to express it at a detectable level. Accordingly, polynucleotides encoding
polypeptide can be conveniently obtained from a cDNA library prepared from human tissue. The
polypeptide-encoding gene may also be obtained from a genomic library or by known synthetic
procedures (e.g., automated nucleic acid synthesis).
For example, the polynucleotide may encode an entire immunoglobulin molecule
chain, such as a light chain or a heavy chain. A complete heavy chain includes not only a heavy
chain variable region (V ) but also a heavy chain constant region (C ), which typically will
comprise three constant domains: C 1, C 2 and C 3; and a "hinge" region. In some situations,
H H H
the presence of a constant region is desirable.
Other polypeptides which may be encoded by the polynucleotide include antigen-
binding antibody fragments such as single domain antibodies (“dAbs”), Fv, scFv, Fab' and
F(ab') and “minibodies.” Minibodies are (typically) bivalent antibody fragments from which the
C 1 and C or C domain has been excised. As minibodies are smaller than conventional
H K L
antibodies they should achieve better tissue penetration in clinical/diagnostic use, but being
bivalent they should retain higher binding affinity than monovalent antibody fragments, such as
dAbs. Accordingly, unless the context dictates otherwise, the term "antibody" as used herein
encompasses not only whole antibody molecules but also antigen-binding antibody fragments of
the type discussed above. Preferably each framework region present in the encoded polypeptide
will comprise at least one amino acid substitution relative to the corresponding human acceptor
framework. Thus, for example, the framework regions may comprise, in total, three, four, five,
six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen amino acid substitutions
relative to the acceptor framework regions.
Suitably, the polynucleotides described herein may be isolated and/or purified. In some
embodiments, the polynucleotides are isolated polynucleotides.
The term “isolated polynucleotide” is intended to indicate that the molecule is removed
or separated from its normal or natural environment or has been produced in such a way that it is
not present in its normal or natural environment. In some embodiments, the polynucleotides are
purified polynucleotides. The term purified is intended to indicate that at least some
contaminating molecules or substances have been removed.
Suitably, the polynucleotides are substantially purified, such that the relevant
polynucleotides constitutes the dominant (i.e., most abundant) polynucleotides present in a
composition.
(B) Expression of Polynucleotides
The description below relates primarily to production of polypeptides by culturing cells
transformed or transfected with a vector containing polypeptide-encoding polynucleotides. It is,
of course, contemplated that alternative methods, which are well known in the art, may be
employed to prepare polypeptides. For instance, the appropriate amino acid sequence, or
portions thereof, may be produced by direct peptide synthesis using solid-phase techniques (see,
e.g., Stewart et al., Solid-Phase Peptide Synthesis W.H. Freeman Co., San Francisco, Calif.
(1969); Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1963)). In vitro protein synthesis may be
performed using manual techniques or by automation. Automated synthesis may be
accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City,
Calif.) using manufacturer's instructions. Various portions of the polypeptide may be chemically
synthesized separately and combined using chemical or enzymatic methods to produce the
desired polypeptide.
Polynucleotides as described herein are inserted into an expression vector(s) for
production of the polypeptides. The term “control sequences” refers to DNA sequences
necessary for the expression of an operably linked coding sequence in a particular host
organism. The control sequences include, but are not limited to, promoters (e.g., naturally-
associated or heterologous promoters), signal sequences, enhancer elements, and transcription
termination sequences.
A polynucleotide is “operably linked” when it is placed into a functional relationship
with another polynucleotide sequence. For example, nucleic acids for a presequence or secretory
leader is operably linked to nucleic acids for a polypeptide if it is expressed as a preprotein that
participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a
coding sequence if it affects the transcription of the sequence; or a ribosome binding site is
operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally,
“operably linked” means that the nucleic acid sequences being linked are contiguous, and, in the
case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to
be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites
do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with
conventional practice.
For antibodies, the light and heavy chains can be cloned in the same or different
expression vectors. The nucleic acid segments encoding immunoglobulin chains are operably
linked to control sequences in the expression vector(s) that ensure the expression of
immunoglobulin polypeptides.
The vectors containing the polynucleotide sequences (e.g., the variable heavy and/or
variable light chain encoding sequences and optional expression control sequences) can be
transferred into a host cell by well-known methods, which vary depending on the type of cellular
host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells,
whereas calcium phosphate treatment, electroporation, lipofection, biolistics or viral-based
transfection may be used for other cellular hosts. (See generally Sambrook et al., Molecular
Cloning: A Laboratory Manual (Cold Spring Harbor Press, 2nd ed., 1989). Other methods used
to transform mammalian cells include the use of polybrene, protoplast fusion, liposomes,
electroporation, and microinjection. For production of transgenic animals, transgenes can be
microinjected into fertilized oocytes, or can be incorporated into the genome of embryonic stem
cells, and the nuclei of such cells transferred into enucleated oocytes.
(C) Vectors
The term “vector” includes expression vectors and transformation vectors and shuttle
vectors.
The term “expression vector” means a construct capable of in vivo or in vitro
expression.
The term “transformation vector” means a construct capable of being transferred from
one entity to another entity - which may be of the species or may be of a different species. If the
construct is capable of being transferred from one species to another - such as from an
Escherichia coli plasmid to a bacterium, such as of the genus Bacillus, then the transformation
vector is sometimes called a “shuttle vector”. It may even be a construct capable of being
transferred from an E. coli plasmid to an Agrobacterium to a plant.
Vectors may be transformed into a suitable host cell as described below to provide for
expression of a polypeptide. Various vectors are publicly available. The vector may, for
example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic
acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is
inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
Construction of suitable vectors containing one or more of these components employs standard
ligation techniques which are known to the skilled artisan.
The vectors may be for example, plasmid, virus or phage vectors provided with an
origin of replication, optionally a promoter for the expression of the said polynucleotide and
optionally a regulator of the promoter. Vectors may contain one or more selectable marker genes
which are well known in the art.
These expression vectors are typically replicable in the host organisms either as
episomes or as an integral part of the host chromosomal DNA.
(D) Host Cells
The host cell may be a bacterium, a yeast or other fungal cell, insect cell, a plant cell,
or a mammalian cell, for example.
A transgenic multicellular host organism which has been genetically manipulated may
be used to produce a polypeptide. The organism may be, for example, a transgenic mammalian
organism (e.g., a transgenic goat or mouse line).
Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative
or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli. Various E. coli
strains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776
(ATCC 31,537); E. coli strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other
suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, e.g., E. coli,
Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia,
e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis
(e.g., B. licheniformis 41P), Pseudomonas such as P. aeruginosa, and Streptomyces. These
examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or
parent host because it is a common host strain for recombinant polynucleotide product
fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For
example, strain W3110 may be modified to effect a genetic mutation in the genes encoding
polypeptides endogenous to the host, with examples of such hosts including E. coli W3110
strain 1A2, which has the complete genotype tonA; E. coli W3110 strain 9E4, which has the
complete genotype tonA ptr3; E. coli W3110 strain 27C7 (ATCC 55,244), which has the
complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan'; E. coli W3110 strain
37D6, which has the complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7
ilvG kan'; E. coli W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant degP
deletion mutation; and an E. coli strain having mutant periplasmic protease. Alternatively, in
vitro methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.
In these prokaryotic hosts, one can make expression vectors, which will typically
contain expression control sequences compatible with the host cell (e.g., an origin of
replication). In addition, any number of a variety of well-known promoters will be present, such
as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter
system, or a promoter system from phage lambda. The promoters will typically control
expression, optionally with an operator sequence, and have ribosome binding site sequences and
the like, for initiating and completing transcription and translation.
Eukaryotic microbes may be used for expression. Eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding
vectors. Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism.
Others include Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis
(MW98-8C, CBS683, CBS4574), K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K.
wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K.
thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris; Candida;
Trichoderma reesia; Neurospora crassa; Schwanniomyces such as Schwanniomyces
occidentalis; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and
Aspergillus hosts such as A. nidulans, and A. niger. Methylotropic yeasts are suitable herein and
include, but are not limited to, yeast capable of growth on methanol selected from the genera
consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and
Rhodotorula. Saccharomyces is a preferred yeast host, with suitable vectors having expression
control sequences (e.g., promoters), an origin of replication, termination sequences and the like
as desired. Typical promoters include 3-phosphoglycerate kinase and other glycolytic enzymes.
Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase,
isocytochrome C, and enzymes responsible for maltose and galactose utilization.
In addition to microorganisms, mammalian tissue cell culture may also be used to
express and produce the polypeptides as described herein and in some instances are preferred
(See Winnacker, From Genes to Clones VCH Publishers, N.Y., N.Y. (1987). For some
embodiments, eukaryotic cells may be preferred, because a number of suitable host cell lines
capable of secreting heterologous polypeptides (e.g., intact immunoglobulins) have been
developed in the art, and include CHO cell lines, various Cos cell lines, HeLa cells, preferably,
myeloma cell lines, or transformed B-cells or hybridomas. In some embodiments, the
mammalian host cell is a CHO cell.
In some embodiments, the host cell is a vertebrate host cell. Examples of useful
mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC
CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension
culture); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-
DHFR(CHO or CHO-DP-12 line); mouse sertoli cells; monkey kidney cells (CV1 ATCC CCL
70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical
carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo
rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human
liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI
cells; MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
V. Formulations and Methods of Making of the Formulations
Provided herein are also formulations and methods of making the formulation
comprising the polypeptides (e.g., antibodies) purified by the methods described herein. For
example, the purified polypeptide may be combined with a pharmaceutically acceptable carrier.
The polypeptide formulations in some embodiments may be prepared for storage by
mixing a polypeptide having the desired degree of purity with optional pharmaceutically
acceptable carriers, excipients or stabilizers (Remington’s Pharmaceutical Sciences 16th edition,
Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
“Carriers” as used herein include pharmaceutically acceptable carriers, excipients, or
stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and
concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered
solution.
Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages
and concentrations employed, and include buffers such as phosphate, citrate, and other organic
acids; antioxidants including ascorbic acid and methionine; preservatives (such as
octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium
chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl
or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular
weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as
glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides,
and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as
EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as
TWEEN™, PLURONICS™ or polyethylene glycol (PEG).
In some embodiments, the polypeptide in the polypeptide formulation maintains
functional activity.
The formulations to be used for in vivo administration must be sterile. This is readily
accomplished by filtration through sterile filtration membranes.
The formulations herein may also contain more than one active compound as necessary
for the particular indication being treated, preferably those with complementary activities that do
not adversely affect each other. For example, in addition to a polypeptide, it may be desirable to
include in the one formulation, an additional polypeptide (e.g., antibody). Alternatively, or
additionally, the composition may further comprise a chemotherapeutic agent, cytotoxic agent,
cytokine, growth inhibitory agent, anti-hormonal agent, and/or cardioprotectant. Such molecules
are suitably present in combination in amounts that are effective for the purpose intended.
V. Articles of Manufacture
The polypeptides purified by the methods described herein and/or formulations
comprising the polypeptides purified by the methods described herein may be contained within
an article of manufacture. The article of manufacture may comprise a container containing the
polypeptide and/or the polypeptide formulation. Preferably, the article of manufacture
comprises:(a) a container comprising a composition comprising the polypeptide and/or the
polypeptide formulation described herein within the container; and (b) a package insert with
instructions for administering the formulation to a subject.
The article of manufacture comprises a container and a label or package insert on or
associated with the container. Suitable containers include, for example, bottles, vials, syringes,
etc. The containers may be formed from a variety of materials such as glass or plastic. The
container holds or contains a formulation and may have a sterile access port (for example the
container may be an intravenous solution bag or a vial having a stopper pierceable by a
hypodermic injection needle). At least one active agent in the composition is the polypeptide.
The label or package insert indicates that the composition’s use in a subject with specific
guidance regarding dosing amounts and intervals of polypeptide and any other drug being
provided. The article of manufacture may further include other materials desirable from a
commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
In some embodiments, the container is a syringe. In some embodiments, the syringe is further
contained within an injection device. In some embodiments, the injection device is an
autoinjector.
A “package insert” is used to refer to instructions customarily included in commercial
packages of therapeutic products, that contain information about the indications, usage, dosage,
administration, contraindications, other therapeutic products to be combined with the packaged
product, and/or warnings concerning the use of such therapeutic products.
VI. Exemplary embodiments
In some embodiments, described are methods for purifying a polypeptide from a
composition comprising the polypeptide and one or more contaminants, said method comprising
a) loading the composition onto a chromatography material in an amount in excess of the
dynamic binding capacity of the chromatography material for the polypeptide, b) eluting the
polypeptide from the chromatography material under conditions wherein the one or more
contaminants remain bound to the chromatography material, and c) pooling fractions comprising
the polypeptide in the chromatography effluent from steps a) and b).
In further embodiments of the above embodiment, polypeptide is an antibody or
immunoadhesin.
In further embodiments of the above embodiment, the polypeptide is an
immunoadhesin.
In further embodiments of the above embodiment, the polypeptide is an antibody.
In further embodiments of the above embodiment, the antibody is a monoclonal
antibody.
In yet a further embodiment of the above embodiment, the monoclonal antibody is a
chimeric antibody, humanized antibody, or human antibody.
In further embodiments of the above embodiment, the monoclonal antibody is an IgG
monoclonal antibody.
In further embodiments of the above embodiment, the antibody is an antigen binding
fragment.
In yet further embodiments of the above embodiment, the antigen binding fragment is
selected from the group consisting of a Fab fragment, a Fab’ fragment, a F(ab’)2 fragment, a
scFv, a di-scFv, a bi-scFv, a tandem (di, tri)-scFv, a Fv, a sdAb, a tri-functional antibody, a
BiTE, a diabody and a triabody.
In further embodiments of the above embodiment, the polypeptide is selected from an
enzyme, a hormone, a fusion protein, an Fc-containing protein, an immunoconjugate, a cytokine
and an interleukin.
In further embodiments of the above embodiment, the at least one contaminant is any
one or more of Chinese Hamster Ovary Protein (CHOP), a host cell protein (HCP), leached
protein A, carboxypeptidase B, nucleic acid, DNA, product variants, aggregated protein, cell
culture media component, gentamicin, polypeptide fragment, endotoxin and viral contaminant.
In further embodiments of the above embodiment, the chromatography material is
selected from a mixed mode material, an anion exchange material, a cation exchange material, a
hydrophobic interaction material, and an affinity material.
In further embodiments of the above embodiment, the loading density is between about
50 g/L to about 2000 g/L.
In yet further embodiments of the above embodiment; the loading density is between
about 200 g/L to about 1000 g/L.
In further embodiments of the above embodiment, the composition is loaded onto the
chromatography material at about the dynamic binding capacities of the chromatography
materials for the one or more contaminants.
In further embodiments of the above embodiment, the composition is loaded on the
chromatography material at 20-times the dynamic binding capacity of the chromatography
material for the polypeptide.
In further embodiments of the above embodiment, the partition coefficient of the
chromatography material for the polypeptide is greater than 30.
In yet further embodiments of the above embodiment, the partition coefficient of the
chromatography material for the polypeptide is greater than 100.
In further embodiments of the above embodiment, the method further comprises the
use of a loading buffer and an elution buffer.
In further embodiments of the above embodiment, the elution buffer has a conductivity
less than the conductivity of the loading buffer.
In further embodiments of the above embodiment, the loading buffer has a
conductivity of about 4.0 mS to about 7.0 mS.
In further embodiments of the above embodiment, the elution buffer has a conductivity
of about 0.0 mS to about 7.0 mS.
In further embodiments of the above embodiment, the elution buffer has a conductivity
greater than the conductivity of the loading buffer.
In further embodiments of the above embodiment, the loading buffer has a
conductivity of about 4.0 mS to about 7.0 mS.
In further embodiments of the above embodiment, the elution buffer has a conductivity
of about 5.5 mS to about 17.0 mS.
In further embodiments of the above embodiment, the conductivity of the elution
buffer decreases in a gradient from about 5.5 mS to about 1.0 mS over about 10 column volumes
(CVs).
In further embodiments of the above embodiment, the conductivity of the elution
buffer decreases in a gradient from about 5.5 mS to about 1.0 mS over about 15 CVs.
In further embodiments of the above embodiment, the conductivity of the elution
buffer decreases in a gradient from about 10.0 mS to about 1.0 mS over about 5 CVs.
In further embodiments of the above embodiment, the conductivity of the elution
buffer decreases in a gradient from about 10.9 mS to about 1.0 mS over about 10 CVs.
In further embodiments of the above embodiment, the elution buffer has a pH less than
the pH of the loading buffer.
In further embodiments of the above embodiment, the loading buffer has a pH of about
4 to about 9.
In further embodiments of the above embodiment, the elution buffer has a pH of about
4 to about 9.
In further embodiments of the above embodiment, the elution buffer has a pH greater
than the pH of the loading buffer.
In further embodiments of the above embodiment, the load buffer has a pH of about 4
to about 9.
In further embodiments of the above embodiment, the elution buffer has a pH of about
4 to about 9.
In further embodiments of the above embodiment, the composition is an eluent from an
affinity chromatography, a cation exchange chromatography, an anion exchange
chromatography, a mixed mode chromatography and a hydrophobic interaction chromatography.
In further embodiments of the above embodiment, the affinity chromatography is a
Protein A chromatography.
In further embodiments of the above embodiment, the polypeptide is further purified.
In yet further embodiments of the above embodiment, the polypeptide is further
purified by virus filtration.
In yet further embodiments of the above embodiment, the polypeptide is further
purified by one or more of an affinity chromatography, a cation exchange chromatography, an
anion exchange chromatography, a mixed mode chromatography or a hydrophobic interaction
chromatography.
In further embodiments of the above embodiment, the polypeptide is further
concentrated.
In yet further embodiments of the above embodiment, the polypeptide is concentrated
by ultrafiltration, diafilteration or a combination of ultrafiltration and diafiltration.
In further embodiments of the above embodiment, the methods further comprising
combining the polypeptide with a pharmaceutically acceptable carrier.
All of the features disclosed in this specification may be combined in any combination.
Each feature disclosed in this specification may be replaced by an alternative feature serving the
same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature
disclosed is only an example of a generic series of equivalent or similar features.
Further details of the invention are illustrated by the following non-limiting Examples.
The disclosures of all references in the specification are expressly incorporated herein by
reference.
EXAMPLES
The examples below are intended to be purely exemplary of the invention and should
therefore not be considered to limit the invention in any way. The following examples and
detailed description are offered by way of illustration and not by way of limitation.
Materials and Methods
Materials and methods for all Examples were performed as indicated below unless
otherwise noted in the Example.
MAb feedstocks
MAb feedstocks for all examples were selected from industrial, pilot or small scale cell
culture batches at Genentech (South San Francisco, CA, U.S.A.). After a period of cell culture
fermentation, the cells were separated and the clarified fluid was purified by Protein A
chromatography. The Protein A pool was used to investigate the mechanism of impurity
clearance. Table 2 shows feedstock characteristics for each mAb used in the examples.
Table2. Characteristics of MAb feedstocks.
MAb MAb pI
indentification
MAb 1 Rituxan 8.8-9.3
MAb 2 anti-oxLDL 9.3
MAb 3 anti-IFN α 8.7
MAb 4 Xolair 7.6
MAb 5 anti-FGFR3 8.1
MAb quantification
The concentration of antibody was determined via absorbance at 280 and 320 nm using
a UV-visible spectrophotometer (8453 model G1103A; Agilent Technologies; Santa Clara, CA,
U.S.A.) or NanoDrop 1000 model ND-1000 (Thermo Fisher Scientific; Waltham, MA, U.S.A.).
Species other than antibody (i.e. impurities) were too low in concentration to have an
appreciable effect on UV absorbance. As needed, samples were diluted with an appropriate non-
interfering diluent in the range of 0.1–1.0 absorbance unit. Sample preparation and UV
measurements were performed in duplicate and the average value was recorded. The MAb
absorption coefficients ranged from 1.42 to 1.645/mg·ml·cm.
CHO host cell protein (CHOP) quantification
An ELISA was used to quantify the levels of the host cell protein called CHOP. Anti-
CHOP antibodies were immobilized on microtiter plate wells. Dilutions of the samples
containing CHOP, standards and controls were incubated in the wells, followed by incubation
with anti-CHOP antibodies conjugated with horseradish peroxidase (HRP). The HRP enzymatic
activity was detected with o-phenylenediamine, and the CHOP was quantified by reading
absorbance at 490 nm in a microtiter plate reader. Based on the principles of sandwich ELISA,
the concentration of peroxidase corresponded to the CHOP concentration. The assay range for
the ELISA was typically 5–320 ng/ml with intra-assay variability <10 %. CHOP values were
reported in units of ng/ml. Alternatively, CHOP values were divided by the MAb concentration
and the results were reported in PPM (parts per million; e.g. ng of CHOP/mg of MAb). The
CHOP ELISA may be used to quantify total CHOP levels in a sample but does not quantify the
concentration of individual proteins.
Chromatography Operating Conditions
Capto Adhere and Capto MMC Capto Adhere resins were obtained from GE
Healthcare (Uppsala, Sweden). Strong cation exchange resins (Poros XS and Poros 50 HS)
were obtained from Applied Biosystems (Address). All laboratory chromatographic
experiments were carried out using an AKTA FPLC chromatographic system from GE
Healthcare (Uppsala, Sweden) utilizing UNICORN software. Laboratory columns were 0.66 cm
in diameter and 10–20 cm in height. The columns were equilibrated to the specified operating
conditions of pH and conductivity prior to loading. Protein A pools were then loaded on to the
column followed by the elution buffer as required to elute off the bound protein. The
flowthrough or eluate during the load, overload and elution phases were collected as fractions
and then analyzed for impurities. MAb load density varied from 100 to 1000 g per liter of resin.
Chromatography Pool Analysis
The flow-through pools during the load, overload and the elution phases were collected
in fractions (1 column volume each) and analyzed for MAb concentration, CHOP concentration,
aggregates, Leached Protein A, CHO DNA and yield. Cumulative plots were generated as a
function of the elution pool fractions. Cumulative yield was obtained using Equation 1.
where, for fraction i, Ci is the Mab concentration (mg/ml), Vi is the volume of the
fraction (ml), Mp is the mass of protein loaded (mg).
C * V
i = 1
*100
Cumulative % Yield = Equation 1
Size-Exclusion Chromatography
The size heterogeneity of the monoclonal antibodies was determined by a high-
performance size exclusion chromatography assay. A TSK G3000SWXL SEC column
(diameter=7.8 mm, height=300 mm; part number 08541) manufactured by Tosoh Bioscience
(Tokyo, Japan) was operated at ambient temperature on a 1200 series HPLC instrument (Agilent
Technologies) and used to determine the relative levels of MAb monomer for the collected
samples. The column was operated at a flow rate of 0.3 mL/min using a 200 mM potassium
phosphate, 250 mM potassium chloride pH 6.2 mobile phase. 20 µg of antibody was injected for
each sample. UV absorbance at 280 nm was used to monitor the separation of monomer, LMW
proteins and HMW proteins. Percentages of monomer, LMW proteins and HMW proteins were
analyzed manually using ChemStation software (Agilent Technologies).
CHO DNA Quantification
CHO DNA in product samples was quantified using real-time PCR (TaqMan PCR).
DNA from samples and controls were first extracted using Qiagen's Virus Biorobot kit. The
extracted samples, controls, and standard DNA, were subject to TaqMan real time Polymerase
chain reaction (PCR) using PCR primers and probe in a 96-well plate with ABI's sequence
detection system. The primers were defined by a 110 base pair segment of a repetitive DNA
sequence in the Cricetulus griseus genome. The probe was labeled with a fluorescent reporter
dye at 5’ end and a quencher dye at the 3’ end. When the probe is intact, the emission spectrum
of the reporter is suppressed by the quencher. The 5’ nuclease activity of polymerase hydrolyzes
the probe and releases the report, which results in an increase in fluorescence emission. The
sequence detector quantified the amplified product in direct proportion to the increase in
fluorescence emission measured continuously during the DNA amplification. Cycle numbers at
which DNA had amplified past the threshold (CT) were calculated for the standard curve. A
standard curve ranging 1 pg/mL-10,000 pg/mL was generated, which was used for quantifying
DNA in samples.
Leached Protein A quantification
The level of leached Protein-A in the Protein A pools was determined by a sandwich
Protein-A ELISA. Chicken anti-staphylococcal protein A antibodies were immobilized on
microtiter plate wells. The sample treatment procedure included sample dilution and then
dissociation of the Protein A/IgG complex using microwave assisted heating as a pretreatment
step before running the samples on a sandwich ELISA. Protein A, if present in the sample,
bound to the coated antibody. Bound protein A was detected using horseradish peroxidase
conjugated anti-protein antibodies. Horseradish peroxidase enzymatic activity was quantified
with a 2 component TMB substrate solution which produces a colorimetric signal.
Feedstock Conditioning
Feedstocks used for experiments in this study were either fresh or were removed from
cold storage (2–8 ˚C or –70 ˚C) and allowed to equilibrate to room temperature. Subsequently,
they were pH and/or conductivity adjusted as necessary using a titrating agent (1.5 M Tris base
or 1 M Acetic acid) or diluent (purified water, 5 M sodium chloride, or 5 M sodium acetate). All
feedstocks were 0.2 μm filtered using a Millipak 20 (Millipore), AcroPakTM 20 (Pall
Corporation) or a vacuum filter (Thermo Fisher Scientific, Rochester, NY, U.S.A.).
High Throughput Screening
A Tecan Freedom Evo 200 robot (Tecan US, Research Triangle Park, NC) was used
for liquid and resin handling. A 96-well filter plate (Seahorse 800 µL polypropylene 0.45µm
short drip filter plates, E&K Scientific EK-2223) was used to incubate resin with the protein and
buffer. After incubating the protein solution with the resin, the filter plate was centrifuged at
1200 x g for 3 minutes to separate the solution from the resin. For each stage, 300 mL of
solution was contacted with 50 mL of resin, resulting in a phase volume ratio of 6:1. Each well
was equilibrated to the appropriate pH and sodium acetate concentration. The pH ranged from
.00 to 7.5 at 0.5 pH unit intervals (acetate was used to buffer the pH 5.00 to 5.5 conditions,
MES was used to buffer the pH 6.00 to 6.5 conditions, and MOPS was used to buffer the 7.00 to
7.5 conditions). All experiments were performed at room temperature. Partially purified
Protein A pool, concentrated to 5 g/L or 97 mg/mL, and buffer exchanged into 15 mM NaOAc
was used as a load for these experiments. Resin was challenged to 5 g/L for the experiments to
determine product K values. However, for the actual product binding capacity the resin was
challenged to 97 g/L. The filtrate solution was captured in a collection plate and then analyzed
using the Infinite M200 plate reader. The bound protein was subsequently stripped from the
resin using two stages of a 2 M NaCl buffer to close the mass balance.
Virus Clearance Studies
The objective of this study was to evaluate virus removal capability of the Capto
Adhere for the 2 model viruses (MMV and X-MuLV). Columns, 0.66 cm diameter, were
packed with naïve resins to a 20 cm bed height. The MAb feed was spiked with 1% virus and
then processed over the Capto Adhere resin. The pools were collected immediately and load and
elution samples were assayed for viral counts. Multiple dilutions of pools with Complete
Medium (1:10 and 1:100) were made to determine any potential interference between the buffer
components and the viruses.
Example 1. High throughput screening
This example describes high throughput screening methods to determine binding
capacities of chromatography material. High throughput screening was performed on Capto
Adhere resin under batch binding conditions for monoclonal antibody MAb3.
The results of high throughput screening of binding conditions are presented in Figure
1. In the response surface figures (Figures 1A and 1B), product-binding regions are indicated by
red (region 8 of Figure 1A and region 7 in Figure 1B) and the product, e.g. polypeptide, non-
binding regions are green (indicated as region 1). The actual host cell protein (HCP) contents
(ng/mg) in the supernatant are shown in the Figure 1C contour plot. Product K as a function of
pH and counterion concentration for MAb3 is shown in Figure 1A. The resin was loaded to 5
g/L and the raw data was analyzed using a response surface model. The model was then used to
estimate the K for any combination of pH and counterion concentration in the experimental
space. Data shows that as the pH increases and as the conductivity increases, the log K
increases. Increases in log K reflect increases in the product binding to the resin. In order to
find out the actual product binding capacity on the resin, the resin was challenged to 80 g/L at 48
different conditions combining different pHs and counterion concentrations (Figure 1B). The
supernatant from the same experimental plate was also analyzed for HCP (ng/mg) and the data
was plotted in the form of contour (Figure1C). Partially purified Protein A pool containing
several thousand ppm of CHOP was used as a load for the high throughput screening
experiments. Green regions (region 1) in the figure indicate the lower amount of CHOP in the
supernatant and the red regions (region 8 of Figure 1B and region 9 of Figure 1C) indicate
higher amount of CHOP in the supernatant.
Design space for optimal loading and elution conditions can be determined from the
CHOP and the binding data contour plots. These plots enable the design of either a flow
through mode of operation or a bind and elute mode of operation. Loading conditions for a
complete Flow Through chromatography are generally conditions where product binding
minimized, e.g. polypeptide binding, and the impurity (CHOP) binding is maximized. Complete
overlapping green regions (region 1) between Figures 1B and 1C suggest that a F/T mode is
possible. However, the green region (region 1) in this plot is a region where the conductivity is
really low ~1mS. Such conditions require about 4-fold dilution of the Protein A pool resulting
in potential plant fit challenges at scale.
The red regions (region 7 in Figure 1B and region 8 in Figure 1C) indicate binding
regions for both MAb and CHOP. There are some overlapping red regions in both the plots.
However, Figure1B shows that, within the operable pHs and counterion concentrations, a
maximum binding capacity of 55 g/L was possible. For a high titer process with a cell culture
titer of ~3.5 g/L, a 1000 L column would be needed to recover all the product, such as a
polypeptide, in one cycle or multiple cycles would have to be performed on a smaller column.
In an OEC mode, a loading condition can be chosen based on the impurity (e.g.
CHOP) behavior on the column. The amount of MAb that binds to the column is less of a
concern because the bound MAb can be recovered by the elution phase. Thus there is an entire
experimental space to design the loading condition so as to get maximum impurity clearance
without being limited by the resin’s product binding capacity. While bind and elute mode
allows 55 g/L load density, OEC enables about a10-fold higher loading capacity thereby
allowing implementation of a smaller column which in turn can reduce resin cost per gram of
product and offers a good plant fit.
Example 2. Optimized OEC mode
HTS data was used for parameter determination to operate in an OEC mode. Based on
load density requirements, plant fit and impurity clearance, the load conditions for MAb 3 were
selected to be pH 6.5 and 5.5 mS/cm. The load density for the optimized chromatography run
shown in Figure 2 was 180 g/L. About 50 g/L polypeptide product binding to the resin during
the load phase. The product pool was collected starting at about 0.5 OD, and the product was
overloaded on the resin up to 180 g/L. After completion of the load phase, elution phase with
low conductivity buffer of 1 mS/cm (elution buffer: 20 mM MES pH 6.5) was used to elute the
bound protein resulting in 10-15% pool volume reduction compared to flow-through
chromatography. Yield and impurity clearance for this chromatography run is shown in Figure
Example 3. Load Optimization
This study was conducted to compare the HTS data and actual column performance
data in the OEC mode of operation. Columns were loaded at three different pH’s. pH 6.5 was
selected to be the best condition based on the initial CHOP clearance and the yield data.
Concentrations of CHOP in the pools ranged from 900 to 50 to 400 ppm as a function of load
pH. From this study, pH 6.5 was determined to be the best condition to load the composition.
In addition, although the yield wasn’t optimized, pH 6.5 also provided the maximum yield
(Figure 3, Table 3).
Table 3. Load condition optimization for an OEC mode
Load Elution Pool CHOP MAb Bound Yield
pH Conductivity pH Conductivity (ppm) (g/L) (%)
(mS/cm) (mS/cm)
8 5.4 8 2.7 895 63 60
6.5 5.6 6.5 2.1 48 49 92
.5 5.3 5.5 3.3 359 29 86
Load CHOP: 20000 ppm
Load Density: 150 g/L
Example 4. Elution optimization
This study was conducted to optimize the elution conditions for OEC. In order to
recover the product (MAb 3, ~50 g/L) that was bound during the load phase, a few column
volumes of wash buffer (50 mM MES, 30 mM NaAcetate, pH 6.5, ~5.5 mS/cm) were passed
through the column after completion of the load phase. A large amount of tailing was observed
resulting in an increase in pool volume at the end of load phase. The increase in pool volume
was about 45% using a wash buffer with a similar pH and conductivity as the load buffer. This
increase in pool volume may result in plant fit challenges (Figure 4).
The objective of elution optimization study was to obtain maximum yield with
minimum CHOP and maximum pool volume reduction. The elution phase was developed for
eluting the 50 g/L of bound product from the column. Figure 5 shows the elution phase of the
chromatograms. Lower conductivity buffer elutes the product off the column within 2 column
volumes resulting in higher yield and lower pool volume (Table 4). Higher conductivity elution
buffers, on the other hand, resulted in tailing of greater than 8 column volumes. As shown in
Table 4, pool CHOP was less than 20 ppm in all the elution buffers tried. Therefore 20 mM
MES was selected as elution buffer to increase yield and to minimize tailing.
Table 4. Elution optimization for OEC
Elution Buffer CHOP (ppm) % Yield
100 mM MES, pH 6.5, 4 mS 13 91
100 mM MES, pH 6.5, 2 mS 11 93
100 mM MES, pH 6.5, 1 mS 17 94
Water 15 90
Load CHOP: 3200 ppm
Load conditions: pH 6.5, 5.5 mS/cm
Load density: 180 g/L
Example 5. Impurity Analysis on OEC
Fractions from OEC were analyzed for impurities. Figure 6A shows the MAb
concentrations and CHOP levels in fractions collected during load phase and during elution
phase. During the load phase, CHOP remained between 20-25 ppm and during the elution phase
where only the bound MAb is being eluted, the fractional CHOP level decreases. Cumulative
analysis demonstrates that the CHOP and other impurities remain fairly consistent across the
entire load and the elution phases (Figure 6B). The load density for this run was 180 g/L. Virus
clearance, using X-MuLV and MMV as model viruses, was also studied for the same load
density (Table 5). For this experiment, load pH was 6.5 and load conductivity was 5.5 mS/cm.
Elution conditions were 20 mM MES pH 6.5 and conductivity of ~1 mS/cm.
Table 5. Virus clearance for OEC mode chromatography.
Capto Adhere resin X-MuLV MMV
load density LRV LRV
180 g/L 3.6 3.3
Example 6. Maximum Impurity Binding Capacity Determination
To find the maximum impurity binding capacity on the resin loaded with MAb3 by
OEC mode, the Capto Adhere resin was challenged to1000 g/L with Protein A pool. Loading
buffer was pH 6.5, ~5.5 mS/cm; elution buffer was 20 mM MES pH 6.5, ~1 mS/cm. Pool
sample was collected every 50 g/L and analyzed for CHOP and protein concentration (Figure 7).
For loading densities of up to 800 g/L, CHOP did not break through and the CHOP in the eluate
was less than 20 ng/mg.
Example 7. Implementation at Pilot Scale
The OEC mode of operation was implemented on pilot scale columns ranging in size
from 1.6 L to 10.8 L. The column diameters ranged from 10 cm to 25 cm with bed heights
ranging from 20 – 22 cm (Table 6). Samples were loaded at pH 6.5, ~5.5 mS/cm and eluted
with 20 mM MES pH 6.5, ~ 1 mS/cm. Yield across the pilot scale runs are shown in Figure 8.
The load densities in the pilot scale runs covered a range of load densities anywhere from 70 to
180 g/L. Across all the load densities, an average yield of 94% was achieved. There was no
impact on yield over the range of load densities tested. Across all pilot scale runs, the OEC
mode pool CHOP was less than 25 ppm which was then cleared downstream to <2 ppm CHOP
in the final polypeptide product (UFDF pool) (Table 7). On average, there was about 1.1%
reduction in HMW proteins across all the pilot scale runs (Table 8) and 0.19% reduction in
LMW proteins across all the pilot scale runs (Table 9).
Table 6. Capto Adhere column size for pilot scale runs
Pilot Scale Run BH Diameter (cm) CV (L)
Run 1 21 10 1.6
Run 2 21 10 1.6
Run 3 20 14 3.1
Run 4 19 14 2.9
Run 5 19 14 2.9
Run 6 22 25 10.8
Run 7 22 25 10.8
Run 8 21.5 10 1.7
Run 9 20 14 3.1
Run 10 22 25 10.8
Table 7. Pilot Scale CHOP data
Steps Run Run Run Run Run Run Run Run Run Run Run Run
1 2 3 4 5 6 7 8 9 10 11 12
HCCF 467000 446000 242000 343000 223000 310000 424000 355000 218000 329000 29700 21500
Protein
A 11360 2200* 5712 9100 5100 4800 5400 6200 9000 7300 5300 4800
Pool
Capto
Adhere
13 14 21 11 22 17 17 13 15 25 17 9
Resin
(OEC)
* CHOP after depth filtration at pH 6.5
HCCF is harvested cell culture fluid
Table 8. Average % HMW proteins reduction across 12 Pilot Scale runs.
Avg % HMW protein Reduction 0.95 ± 0.49
Table 9. Average % LMW proteins reduction across 12 Pilot Scale runs.
Avg % LMW protein Reduction 0.19 ± 0.08
CHO DNA and leached Protein A were less than detectable in the pool after OEC.
Example 8. Implementation at Manufacturing Scale
OEC mode of operation was implemented on a manufacturing scale column with a size
of 157 L (100 cm diameter × 20 cm height). At manufacturing scale, the column was loaded to
~96 g/L. % yield across the two runs at manufacturing scale was ≥95% for both runs. Across
all the manufacturing scale runs, the OEC mode pool CHOP was less than 17 ppm (Table 10)
which was cleared downstream to less than the detectable level of CHOP. In an average, there
was about 1.1% reduction in HMWs, 0.1% reduction in LMWs, and 1.65% reduction in acidics
across the two manufacturing scale runs.
Table 10. Manufacturing Scale CHOP (ppm) data
Steps Run 1 Run 2
HCCE 30500 32500
Protein A Pool 5749 6157
Capto Adhere Resin (OEC) 16 17
CHO DNA and leached Protein A were less than detectable in the pool after OEC
mode.
Example 9. OEC Applicability to outher MAbs
Protein A pools were used as loads for these runs. Load and elution conditions were
selected so as to enable OEC mode. Load densities, % yield, MAb bound to the resin (g/L),
impurities in the load and pool are shown in the following tables (Table 11, 12, 13 and 14).
Table 11. OEC applicability to other MAbs: CHOP
MAb, Load pH Load Elution pH and MAb Load Pool
(conductivity Density conductivity Bound CHOP CHOP
Yield
<6mS/cm) (g/L) (g/L) (ppm) (ppm)
MAb 1, pH 8.6 200 pH 6.5, 1 mS/cm 35 2825 9 93
MAb 2, pH 8.6 200 pH 6.5, 1 mS/cm 24 5057 12 100
MAb 3, pH 6.5 200 pH 6.5, 1 mS/cm 45 3200 15 97
MAb 4, pH 6.1 200 pH 6.0, 0.65 mS/cm 59 193 4 93
MAb 5, pH 5.5 200 pH 4.9, 1.1 mS/cm 59 4560 145 92
Table 12. OEC applicability to other MAbs: % HMW proteins
MAb, Load pH Load Elution pH and MAb Load % Pool
(conductivity Density conductivity Bound HMW % HMW
< 6 mS/cm) (g/L) (g/L) proteins proteins
MAb 1, pH 8.6 200 pH 6.5, 1 mS/cm 35 5.4 1.6
MAb 2, pH 8.6 200 pH 6.5, 1 mS/cm 24 5.4 3.8
MAb 3, pH 6.5 200 pH 6.5, 1 mS/cm 45 3.5 1.8
MAb 4, pH 6.1 200 pH 6.0, 0.65 mS/cm 59 1.9 0.5
MAb 5, pH 5.5 200 pH 4.9, 1.1 mS/cm 59 2.4 1.7
Table 13. OEC applicability to other MAbs: % leached protein A
MAb, Load Load Elution pH and MAb Load Pool
pH Density conductivity Bound Leached Leached
(conductivity (g/L) (g/L) Protein A Protein
<6mS/cm) (ppm) A
(ppm)
MAb 1, pH 8.6 200 pH 6.5, 1 mS/cm 35 2 LTD
MAb 2, pH 8.6 200 pH 6.5, 1 mS/cm 24 2 LTD
MAb 3, pH 6.5 200 pH 6.5, 1 mS/cm 45 3 LTD
MAb 4, pH 6.1 200 pH 6.0, 0.65 mS/cm 59 2 LTD
MAb 5, pH 5.5 200 pH 4.9, 1.1 mS/cm 59 6 LTD
Less than detectable
Table 14. OEC applicability to other MAbs: CHO DNA
Elution pH and Pool
MAb, Load pH Load MAb Load CHO
conductivity CHO
(conductivity <6 Density Bound DNA
mS/cm) (g/L) (g/L) (pg/mL)
(pg/mL)
MAb 1, pH 8.6 200 pH 6.5, 1 mS/cm 35 253 LTD
MAb 2, pH 8.6 200 pH 6.5, 1 mS/cm 24 297 LTD
MAb 3, pH 6.5 200 pH 6.5, 1 mS/cm 45 106 LTD
MAb 4, pH 6.1 200 pH 6.0, 0.65 mS/cm 59 17 LTD
MAb 5, pH 5.5 200 pH 4.9, 1.1 mS/cm 59 4 LTD
Example 10. Modes of AEX chromatography operations based on Kp values
In complete flow through (F/T) chromatography, K is <0.1 and there is no protein
binding to the resin. In weak partitioning chromatography (WPC), K is 0.1 to 20 and there is
weak partitioning between the product and the chromatography media. In a bind and elute
mode, product is tightly bound to the resin, and the K is >100 but the load density is limited to
the product binding capacity. However, in an overload and elute mode of chromatography
(MAb 3), load conditions were found such that the product and the impurities K were >100 and
although the product flows through after reaching its binding capacity, the impurities keep
binding to the resin and does not break through until they reach their binding capacity, which
could be higher than the product binding capacity.
Elution conditions were found such that the polypeptide product Kp < 2. The bound
product is recovered but majority of the impurities remain bound (impurity K > 100). As such,
this mode enables good impurity clearance while providing very high yield (e.g. ~95%) (Table
).
Table 15. MAb 3 as a model antibody on Capto Adhere resin
Parameters WPC OEC
Load Protein A Pool (MAb 3)
Load Conditions pH 5, 4.4 mS/cm pH 6.5, 5.5 mS/cm
Kp 2.6 >100
Log Kp 0.4 4.15
Load CHOP 20000 ppm
Product Binding (g/L resin) 20 50
Pool CHOP (ppm) 360 50
% Yield 86 95
Chromatograms from column runs under weak partitioning conditions (K = 2.4) and
overload and elute conditions (K >100) display the effects of increasing mAb K on the product
breakthrough regions of the chromatogram (Figure 9). WPC load conditions: pH 5.5, 4.4
mS/cm; WPC wash conditions: 20 mM Acetate pH 5, 4.4 mS/cm. OEC load conditions: pH 6.5,
.5 mS/cm; OEC elution conditions: 20 mM MES pH 6.5, ~1 mS/cm.
Table 16. Analysis of an AEX polishing step for a MAb that binds to AEX resin at
typical flow through process conditions
Mode of Operation F/T B/E OEC
Load Density
~200 50 800
(g/L )
resin
Column Size* 220 L 850 L 52 L
~4CV Elution
Pool Volume 11,000 L ~2500 L
(3400L)
Plant Fit (pool Tank Very large pool volume due to Large column or Better plant fit. Reduces pool
limitation) ~5X load dilution multiple cycles volume by ~ 10 – 40%
Cost of Resin** $ 0.7 Million $2.98 Million $ 0.18 Million
Model antibody: MAb 3
* Assume 12,500 L harvest at 3.5 g/L titer.
** CA resin at $ 3500/L
Example 11. OEC applicability to different resins
Depending on the pI of the molecule, OEC can be applied to the following Multi mode
Resins (Capto Adhere, QMA, MEP Hypercel, HEA Hypercel, PPA Hypercel, Capto MMC).
Polypeptide product binding on the Capto Adhere resin was more hydrophobic in nature and the
bound product could be eluted from the column by lowering the conductivity of the elution
buffer (Figure 5). However, the mode of product binding on the resin and product elution from
the resin is not be limited to hydrophobic interactions and thus OEC mode of operation can be
widely used in other chromatography materials as well. Table 17 demonstrates that OEC can be
applied to other CEX Resins and IEX resins. Elution buffers were 20 mM MES unless otherwise
indicted. The potential of OEC is not limited to the above resins and is currently being
evaluated. Breakthrough analysis of MAb 3 on QMA resin is shown in Figure 10.
Breakthrough analysis of MAb 4 on Capto Adhere resin is shown in Figure 11. Breakthrough
analysis of MAb 4 on Capto MMC resin is shown in Figure 12. Breakthrough analysis of MAb 3
on Capto Adhere resin is shown in Figure 13.
Table 17. OEC applicability to different resins.
Load Elution Load MAb Pool
Load CHOP %
MAb Resin pH Condo pH Condo Density Bound CHOP
(ppm) Yield
(mS/cm) (mS/cm) (g/L) (g/L) (ppm)
Capto 6.5 <5.5 6.5 1
200 50 3200 15 97
MAb 3 Adhere
QMA 6.5 <5.5 6.5 1 103 17 1800 99 93
Poros 5.5 <6 5.5 **
MAb 3* 200 100 9900 370 92
Capto 6.1 <5.5 6.0 0.65
200 59 193 4 93
Adhere
MAb 4
Capto 7 <6 6.5 1
147 10 187 27 93
**Poros XS MAb 3 load conditions: pH 5.5, < 6 mS/cm; Elution conditions: Buffer A – 50 mM
acetate pH 5.5, ~3 mS/cm, Buffer B- 350 mM acetate pH 5.5, ~24 mS/cm, Gradient: 20-85%
over 10 CVs, Pooling: 1-8 CVs.
Example 12. Gradient Elution on OEC
Another objective of elution optimization study was to evaluate the effect of gradient
elution conditions on OEC mode on Capto Adhere resin. Elution phase was developed for
eluting the bound product (Table 18). In a gradient elution run, ionic strength, pH, composition
and concentration of the mobile phase can be varied based on the requirements. Table 18 shows
the run conditions: both the load (pH and conductivity) and the elution (pH and the conductivity
gradient) conditions. All the data shown in the table were obtained from chromatography runs
loaded at 150 g/L load density with MAb 3. These runs were done as proof of concept for
demonstrating that gradient elution can be performed on OEC mode of chromatography and the
gradient slope (concentration of the salt (mM)/Column Volume) can be optimized. It can be seen
that the %HMWS is reduced by 38% on an average when compared to the load (Table 18).
CHOP was reduced to <20 ppm in 5.5 mS/cm conductivity run and the higher conductivity run
at 10 mS/cm, resulted in pool CHOP of ~150 ppm (Table 19).
Table 18. Gradient Elution runs on OEC: %HMWs data
Load Load Gradient Elution Product % HMWS % HMWS
pH Conductivity Conditions Bound (g/L) Load Pool
6.5 5.5 mS/cm 5.5 mS/cm to 1 43 4.0 2.4
mS/cm over 10 CVs
6.5 5.5 mS/cm 5.5 mS/cm to 1mS/cm 43 4.0 2.8
over 15 CVs
6.5 10 mS/cm 10 mS/cm to 1mS/cm 48 3.8 2.4
over 5 CVs
6.5 10 mS/cm 10 mS/cm to 1mS/cm 48 3.9 2.2
over 10 CVs
Table 19. Gradient Elution runs on OEC: CHOP data
Load Load Gradient Elution Load CHOP Pool CHOP
pH Conductivity Conditions (ppm) (ppm)
6.5 5.5 mS/cm 5.5 mS/cm to 1 mS/cm over 3100 17
CVs
6.5 5.5 mS/cm 5.5 mS/cm to 1mS/cm over 3100 19
CVs
6.5 10 mS/cm 10 mS/cm to 1mS/cm over 5 3100 160
6.5 10 mS/cm 10 mS/cm to 1mS/cm over 3100 143
CVs
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such
documents, or such sources of information, in any jurisdiction, are prior art, or form part of the
common general knowledge in the art.
Claims (37)
1. A method for purifying an antibody from a composition comprising the antibody and one or more contaminants, said method comprising a) loading the composition onto a chromatography material in an amount in excess of the dynamic binding capacity of the chromatography material for the antibody, b) eluting the antibody from the chromatography material under conditions wherein the one or more contaminants remain bound to the chromatography material, and c) pooling fractions comprising the antibody in the chromatography effluent from steps a) and b), wherein the loading density of the composition is between about 200 g/L to about 1000 g/L and wherein the method further comprises the use of a loading buffer and an elution buffer, wherein the elution buffer has a conductivity less than the conductivity of the loading buffer.
2. The method of claim 1, wherein the antibody is a monoclonal antibody.
3. The method of claim 1 or claim 2, wherein the monoclonal antibody is a chimeric antibody, humanized antibody, or human antibody.
4. The method of claim 2 or claim 3, wherein the monoclonal antibody is an IgG monoclonal antibody.
5. The method of claim 1, wherein the antibody is an antigen binding fragment.
6. The method of claim 5, wherein the antigen binding fragment is a Fab fragment, a Fab’ fragment, a F(ab’) fragment, a scFv, a di-scFv, a bi-scFv, a tandem (di, tri)-scFv, a Fv, a sdAb, a tri- functional antibody, a BiTE, a diabody or a triabody.
7. The method of any one of claims 1-6, wherein the at least one contaminant is any one or more of Chinese Hamster Ovary Protein (CHOP), a host cell protein (HCP), leached protein A, carboxypeptidase B, nucleic acids, DNA, product variants, aggregated protein, cell culture media component, gentamicin, polypeptide fragment, endotoxin and viral contaminant.
8. The method of any one of claims 1-7, wherein the chromatography material is a mixed mode material, an anion exchange material, a hydrophobic interaction material, or an affinity material.
9. The method of any one of claims 1-8 wherein the composition is loaded onto the chromatography material at about the dynamic binding capacities of the chromatography materials for the one or more contaminants.
10. The method of any one of claims 1-9, wherein the composition is loaded on the chromatography material at 20-times the dynamic binding capacity of the chromatography material for the antibody.
11. The method of any one of claims 1-10, wherein the partition coefficient of the chromatography material for the antibody is greater than 30.
12. The method of claim 11, wherein the partition coefficient of the chromatography material for the antibody is greater than 100.
13. The method of any one of claims 1-12, wherein the loading buffer has a conductivity of about 4.0 mS to about 7.0 mS.
14. The method of any one of claims 1-12, wherein the elution buffer has a conductivity of about 0.0 mS to about 7.0 mS.
15. The method of claim 1, wherein the elution buffer has a conductivity greater than the conductivity of the loading buffer.
16. The method of claim 15, wherein the loading buffer has a conductivity of about 4.0 mS to about 10.0 mS.
17. The method of claim 15, wherein the loading buffer has a conductivity of about 4.0 mS to about 7.0 mS.
18. The method of claim 15, wherein the elution buffer has a conductivity of about 5.5 mS to about 17.0 mS.
19. The method of any one of claims 1-12, wherein the conductivity of the elution buffer decreases in a gradient from about 5.5 mS to about 1.0 mS over about 10 column volumes (CVs).
20. The method of any one of claims 1-12, wherein the conductivity of the elution buffer decreases in a gradient from about 5.5 mS to about 1.0 mS over about 15 CVs.
21. The method of any one of claims 1-12, wherein the conductivity of the elution buffer decreases in a gradient from about 10.0 mS to about 1.0 mS over about 5 CVs.
22. The method of any one of claims 1-12, wherein the conductivity of the elution buffer decreases in a gradient from about 10.9 mS to about 1.0 mS over about 10 CVs.
23. The method of any one of claims 1-12, wherein the elution buffer has a pH less than the pH of the loading buffer.
24. The method of claim 23, wherein the load buffer has a pH of about 4 to about 9.
25. The method of claim 23, wherein the elution buffer has a pH of about 4 to about 9.
26. The method of any one of claims 1-12, wherein the elution buffer has a pH greater than the pH of the loading buffer.
27. The method of claim 26, wherein the load buffer has a pH of about 4 to about 9.
28. The method of claim 27, wherein the elution buffer has a pH of about 4 to about 9.
29. The method of any one of claims 1-28, wherein the composition is an eluent from an affinity chromatography, a cation exchange chromatography, an anion exchange chromatography, a mixed mode chromatography or a hydrophobic interaction chromatography.
30. The method of claim 29, wherein the affinity chromatography is a Protein A chromatography.
31. The method of any one of claims 1-30, wherein the antibody is further purified.
32. The method of claim 31, wherein the antibody is further purified by virus filtration.
33. The method of claim 31, wherein the antibody is further purified by one or more of an affinity chromatography, a cation exchange chromatography, an anion exchange chromatography, a mixed mode chromatography and a hydrophobic interaction chromatography.
34. The method of any one of claims 1-33, wherein the antibody is further concentrated.
35. The method of claim 34, wherein the antibody is concentrated by ultrafiltration, diafiltration or a combination of ultrafiltration and diafiltration.
36. The method of any one of claims 31-35 further comprising combining the antibody with a pharmaceutically acceptable carrier.
37. A method as defined in any one of claims 1-36 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161554898P | 2011-11-02 | 2011-11-02 | |
US61/554,898 | 2011-11-02 | ||
PCT/US2012/063242 WO2013067301A1 (en) | 2011-11-02 | 2012-11-02 | Overload and elute chromatography |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624317A NZ624317A (en) | 2016-06-24 |
NZ624317B2 true NZ624317B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210206836A1 (en) | Overload and elute chromatography | |
US20220064209A1 (en) | Methods of purifying polypeptides | |
US10940401B2 (en) | Method for chromatography reuse | |
US20220203347A1 (en) | Method for regeneration of an overload chromatography column | |
NZ624317B2 (en) | Overload and elute chromatography |